<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Bull World Health Organ</journal-id><journal-id journal-id-type="iso-abbrev">Bull. World Health Organ</journal-id><journal-id journal-id-type="publisher-id">BLT</journal-id><journal-title-group><journal-title>Bulletin of the World Health Organization</journal-title></journal-title-group><issn pub-type="ppub">0042-9686</issn><issn pub-type="epub">1564-0604</issn><publisher><publisher-name>World Health Organization</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28804167</article-id><article-id pub-id-type="pmc">5537747</article-id><article-id pub-id-type="publisher-id">BLT.16.185314</article-id><article-id pub-id-type="doi">10.2471/BLT.16.185314</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>The impact of the roll-out of rapid molecular diagnostic testing for tuberculosis on empirical treatment in Cape Town, South Africa</article-title><trans-title-group xml:lang="fr"><trans-title xml:lang="fr">Impact du d&#x000e9;ploiement de tests rapides de diagnostic mol&#x000e9;culaire de la tuberculose sur les traitements empiriques au Cap, en Afrique du Sud</trans-title></trans-title-group><trans-title-group xml:lang="es"><trans-title xml:lang="es">El impacto de la puesta en marcha de una prueba r&#x000e1;pida de diagn&#x000f3;stico molecular para la tuberculosis en un tratamiento emp&#x000ed;rico en Ciudad del Cabo, Sud&#x000e1;frica</trans-title></trans-title-group><trans-title-group xml:lang="ar"><trans-title xml:lang="ar">&#x00623;&#x0062b;&#x00631; &#x00637;&#x00631;&#x0062d; &#x00627;&#x00644;&#x00627;&#x0062e;&#x0062a;&#x00628;&#x00627;&#x00631;&#x00627;&#x0062a; &#x00627;&#x00644;&#x0062a;&#x00634;&#x0062e;&#x0064a;&#x00635;&#x0064a;&#x00629; &#x00627;&#x00644;&#x0062c;&#x00632;&#x0064a;&#x00626;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00633;&#x00631;&#x0064a;&#x00639;&#x00629; &#x00644;&#x00644;&#x00633;&#x00644; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x00639;&#x00644;&#x00627;&#x0062c; &#x00627;&#x00644;&#x0062a;&#x0062c;&#x00631;&#x0064a;&#x00628;&#x0064a; &#x00641;&#x0064a;&#x000a0;&#x00643;&#x0064a;&#x00628;&#x000a0;&#x0062a;&#x00627;&#x00648;&#x00646;&#x000a0;&#x00628;&#x0062c;&#x00646;&#x00648;&#x00628;&#x000a0;&#x00623;&#x00641;&#x00631;&#x0064a;&#x00642;&#x0064a;&#x00627; </trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title xml:lang="zh">&#x05728;&#x05357;&#x0975e;&#x05f00;&#x0666e;&#x06566;&#x05f00;&#x05c55;&#x07ed3;&#x06838;&#x075c5;&#x05feb;&#x0901f;&#x05206;&#x05b50;&#x08bca;&#x065ad;&#x068c0;&#x06d4b;&#x05bf9;&#x07ecf;&#x09a8c;&#x06027;&#x06cbb;&#x07597;&#x07684;&#x05f71;&#x054cd;</trans-title></trans-title-group><trans-title-group xml:lang="ru"><trans-title xml:lang="ru">&#x00420;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442;&#x0044b; &#x00432;&#x0043d;&#x00435;&#x00434;&#x00440;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x0044d;&#x0043a;&#x00441;&#x0043f;&#x00440;&#x00435;&#x00441;&#x00441;-&#x0043c;&#x00435;&#x00442;&#x0043e;&#x00434;&#x00430; &#x0043c;&#x0043e;&#x0043b;&#x00435;&#x0043a;&#x00443;&#x0043b;&#x0044f;&#x00440;&#x0043d;&#x0043e;&#x00439; &#x00434;&#x00438;&#x00430;&#x00433;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x00438;&#x0043a;&#x00438; &#x00442;&#x00443;&#x00431;&#x00435;&#x00440;&#x0043a;&#x00443;&#x0043b;&#x00435;&#x00437;&#x00430; &#x0043f;&#x00440;&#x00438; &#x0044d;&#x0043c;&#x0043f;&#x00438;&#x00440;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x0043e;&#x0043c; &#x0043b;&#x00435;&#x00447;&#x00435;&#x0043d;&#x00438;&#x00438; &#x00432; &#x0041a;&#x00435;&#x00439;&#x0043f;&#x00442;&#x00430;&#x00443;&#x0043d;&#x00435;, &#x0042e;&#x00436;&#x0043d;&#x00430;&#x0044f; &#x00410;&#x00444;&#x00440;&#x00438;&#x0043a;&#x00430;</trans-title></trans-title-group><alt-title alt-title-type="author-running-head">Sabine Hermans et al.</alt-title><alt-title alt-title-type="title-running-head">Rapid diagnostic test roll-out, South Africa</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Hermans</surname><given-names>Sabine</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Caldwell</surname><given-names>Judy</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kaplan</surname><given-names>Richard</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Cobelens</surname><given-names>Frank</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wood</surname><given-names>Robin</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><aff id="aff1"><label>a</label>The Desmond Tutu HIV Centre, Institute for Infectious Diseases and Molecular Medicine, University of Cape Town Faculty of Health Sciences, Anzio Road, Observatory, Cape Town, 7925, <country>South Africa</country>.</aff><aff id="aff2"><label>b</label>City of Cape Town Health Directorate, Cape Town, <country>South Africa</country>.</aff><aff id="aff3"><label>c</label>Amsterdam Institute for Global Health and Development, Amsterdam, <country>Netherlands</country>.</aff></contrib-group><author-notes><corresp id="cor1">Correspondence to Sabine Hermans (email: <email xlink:href="s.hermans@aighd.org">s.hermans@aighd.org</email>).</corresp></author-notes><pub-date pub-type="ppub"><day>01</day><month>8</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>28</day><month>4</month><year>2017</year></pub-date><volume>95</volume><issue>8</issue><fpage>554</fpage><lpage>563</lpage><history><date date-type="received"><day>19</day><month>9</month><year>2016</year></date><date date-type="rev-recd"><day>01</day><month>2</month><year>2017</year></date><date date-type="accepted"><day>20</day><month>3</month><year>2017</year></date></history><permissions><copyright-statement>(c) 2017 The authors; licensee World Health Organization.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution IGO License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/igo/legalcode">http://creativecommons.org/licenses/by/3.0/igo/legalcode</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any reproduction of this article there should not be any suggestion that WHO or this article endorse any specific organization or products. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL.</license-p></license></permissions><abstract><title>Abstract</title><sec><title>Objective</title><p>To investigate the impact of introducing a rapid test as the first-line diagnostic test for drug-sensitive tuberculosis in Cape Town, South Africa.</p></sec><sec><title>Methods</title><p>Xpert&#x000ae; MTB/RIF (Xpert&#x000ae;), an automated polymerase-chain-reaction-based assay, was rolled out between 2011 and 2013. Data were available on 102&#x02009;007 adults treated for pulmonary tuberculosis between 2010 and 2014. Tuberculosis notification rates per 100&#x02009;000 population were calculated for each calendar year and for each year relative to the test roll-out locally, overall and by bacteriological confirmation. Empirical treatment was defined as treatment given without bacteriological confirmation by Xpert&#x000ae;, sputum smear microscopy or sputum culture.</p></sec><sec><title>Findings</title><p>Between 2010 and 2014, the proportion of human immunodeficiency virus (HIV)-negative patients treated empirically for tuberculosis declined from 23% (2445/10&#x02009;643) to 11% (1149/10&#x02009;089); in HIV-positive patients, it declined from 42% (4229/9985) to 27% (2364/8823). The overall tuberculosis notification rate decreased by 12% and 19% among HIV-negative and HIV-positive patients, respectively; the rate of bacteriologically confirmed cases increased by 1% and 3%, respectively; and the rate of empirical treatment decreased by 56% and 49%, respectively. These changes occurred gradually following the test&#x02019;s introduction and stabilized after 3&#x000a0;years.</p></sec><sec><title>Conclusion</title><p>Roll-out of the rapid test in a setting with a high prevalence of pulmonary tuberculosis and HIV infection was associated with a halving of empirical treatment that occurred gradually after the test&#x02019;s introduction, possibly reflecting the time needed for full implementation. More than a quarter of HIV-positive patients with tuberculosis were still treated empirically, highlighting the diagnostic challenge in these patients.</p></sec></abstract><trans-abstract xml:lang="fr"><title>R&#x000e9;sum&#x000e9;</title><sec><title>Objectif</title><p>Analyser l'impact de l'introduction d'un test rapide comme test initial de diagnostic de la tuberculose pharmacosensible au Cap, en Afrique du Sud.</p></sec><sec><title>M&#x000e9;thodes</title><p>Le test Xpert&#x000ae; MTB/RIF (Xpert&#x000ae;), un test automatis&#x000e9; qui repose sur le principe de l'amplification en cha&#x000ee;ne par polym&#x000e9;rase, a &#x000e9;t&#x000e9; d&#x000e9;ploy&#x000e9; entre 2011 et 2013. Des donn&#x000e9;es &#x000e9;taient disponibles au sujet de 102&#x000a0;007&#x000a0;adultes trait&#x000e9;s contre la tuberculose pulmonaire entre 2010 et 2014. Le taux de signalement de cas de tuberculose pour 100&#x000a0;000&#x000a0;habitants a &#x000e9;t&#x000e9; calcul&#x000e9; pour chaque ann&#x000e9;e civile et pour chaque ann&#x000e9;e de d&#x000e9;ploiement du test &#x000e0; l'&#x000e9;chelon local, global et avec confirmation bact&#x000e9;riologique. Nous avons d&#x000e9;fini les traitements empiriques comme les traitements donn&#x000e9;s sans confirmation bact&#x000e9;riologique par le test Xpert&#x000ae;, examen microscopique de frottis d'expectorations ou culture d'expectorations.</p></sec><sec><title>R&#x000e9;sultats</title><p>Entre 2010 et 2014, la proportion de patients s&#x000e9;ron&#x000e9;gatifs au virus de l'immunod&#x000e9;ficience humaine (VIH) trait&#x000e9;s empiriquement contre la tuberculose est pass&#x000e9;e de 23% (2445/10&#x000a0;643) &#x000e0; 11% (1149/10&#x000a0;089); chez les patients s&#x000e9;ropositifs, elle est pass&#x000e9;e de 42% (4229/9985) &#x000e0; 27% (2364/8823). Le taux global de signalement des cas de tuberculose a baiss&#x000e9; respectivement de 12% et de 19% chez les patients s&#x000e9;ron&#x000e9;gatifs et s&#x000e9;ropositifs au VIH; le taux confirm&#x000e9; bact&#x000e9;riologiquement a augment&#x000e9; respectivement de 1% et de 3%; et le taux d&#x02019;administration de traitements empiriques a baiss&#x000e9; respectivement de 56% et de 49%. Ces changements sont intervenus progressivement apr&#x000e8;s l'introduction du test et se sont stabilis&#x000e9;s au bout de 3&#x000a0;ans.</p></sec><sec><title>Conclusion</title><p>Le d&#x000e9;ploiement du test rapide dans une zone ayant une forte pr&#x000e9;valence de tuberculose pulmonaire et de VIH a &#x000e9;t&#x000e9; associ&#x000e9; &#x000e0; une r&#x000e9;duction de moiti&#x000e9; des traitements empiriques, qui s'est faite progressivement apr&#x000e8;s l'introduction du test -ce qui refl&#x000e8;te peut-&#x000ea;tre le temps n&#x000e9;cessaire &#x000e0; sa mise en &#x00153;uvre int&#x000e9;grale. Plus d'un quart des patients s&#x000e9;ropositifs au VIH atteints de tuberculose &#x000e9;taient encore trait&#x000e9;s empiriquement, ce qui montre les enjeux du diagnostic pour ces patients.</p></sec></trans-abstract><trans-abstract xml:lang="es"><title>Resumen</title><sec><title>Objetivo</title><p>Investigar el impacto de la introducci&#x000f3;n de una prueba r&#x000e1;pida como la prueba de diagn&#x000f3;stico de primera l&#x000ed;nea para la tuberculosis sensible a los medicamentos en Ciudad del Cabo, Sud&#x000e1;frica.</p></sec><sec><title>M&#x000e9;todos</title><p>Entre 2011 y 2013 se implement&#x000f3; Xpert&#x000ae; MTB/RIF (Xpert&#x000ae;), una prueba automatizada basada en una reacci&#x000f3;n en cadena de polimerasa. Se dispuso informaci&#x000f3;n sobre 102&#x000a0;007 adultos tratados de tuberculosis pulmonar entre 2010 y 2014. Se calcularon las tasas de notificaci&#x000f3;n de tuberculosis por cada 100&#x02009;000 habitantes por a&#x000f1;o civil y por a&#x000f1;o en relaci&#x000f3;n con la puesta en marcha de la prueba a nivel local, general y por confirmaci&#x000f3;n bacteriol&#x000f3;gica. El tratamiento emp&#x000ed;rico se defini&#x000f3; como un tratamiento proporcionado sin confirmaci&#x000f3;n bacteriol&#x000f3;gica por parte de Xpert&#x000ae;, microscopia de frotis de esputo o cultivo de esputo.</p></sec><sec><title>Resultados</title><p>Entre 2010 y 2014, el porcentaje de pacientes negativos en el virus de la inmunodeficiencia humana (VIH) tratados de forma emp&#x000ed;rica de tuberculosis cay&#x000f3; de un 23% (2&#x02009;445/10&#x02009;643) a un 11% (1&#x02009;149/10&#x02009;089); en pacientes positivos en VIH, cay&#x000f3; de un 42% (4&#x02009;229/9&#x02009;985) a un 27% (2&#x02009;364/8&#x02009;823). En general, la tasa de notificaci&#x000f3;n de tuberculosis cay&#x000f3; un 12% y un 19% entre pacientes con VIH negativo y positivo, respectivamente; la tasa de casos confirmados a nivel bacteriol&#x000f3;gico aument&#x000f3; un 1% y un 3%, respectivamente; y la tasa de tratamiento emp&#x000ed;rico se redujo un 56% y un 49%, respectivamente. Estos cambios se produjeron de forma gradual tras la implementaci&#x000f3;n de la prueba y se estabilizaron pasados 3 a&#x000f1;os.</p></sec><sec><title>Conclusi&#x000f3;n</title><p>La puesta en marcha de la prueba r&#x000e1;pida en un lugar con una alta prevalencia de tuberculosis pulmonar e infecci&#x000f3;n por VIH se asoci&#x000f3; con una reducci&#x000f3;n a la mitad del tratamiento emp&#x000ed;rico que se aplic&#x000f3; de forma gradual tras la introducci&#x000f3;n de la prueba, reflejando posiblemente el momento necesario para la completa implementaci&#x000f3;n. Aun as&#x000ed;, m&#x000e1;s de un cuarto de los pacientes positivos en VIH y con tuberculosis se sometieron a un tratamiento emp&#x000ed;rico, lo que destaca el problema del diagn&#x000f3;stico en estos pacientes.</p></sec></trans-abstract><trans-abstract xml:lang="ar"><title>&#x00645;&#x00644;&#x0062e;&#x00635; </title><sec><title>&#x00627;&#x00644;&#x0063a;&#x00631;&#x00636; </title><p>&#x00627;&#x00644;&#x00648;&#x00642;&#x00648;&#x00641; &#x00639;&#x00644;&#x00649; &#x0062a;&#x00623;&#x0062b;&#x0064a;&#x00631; &#x00639;&#x00645;&#x00644;&#x0064a;&#x00629; &#x00637;&#x00631;&#x0062d; &#x00627;&#x0062e;&#x0062a;&#x00628;&#x00627;&#x00631; &#x00633;&#x00631;&#x0064a;&#x00639; &#x00643;&#x00627;&#x0062e;&#x0062a;&#x00628;&#x00627;&#x00631; &#x0062a;&#x00634;&#x0062e;&#x0064a;&#x00635;&#x0064a; &#x00623;&#x00648;&#x00644;&#x0064a; &#x00644;&#x00644;&#x00633;&#x00644; &#x00627;&#x00644;&#x00645;&#x00642;&#x00627;&#x00648;&#x00645; &#x00644;&#x00644;&#x00623;&#x0062f;&#x00648;&#x0064a;&#x00629; &#x00641;&#x0064a; &#x00643;&#x0064a;&#x00628; &#x0062a;&#x00627;&#x00648;&#x00646; &#x00628;&#x0062c;&#x00646;&#x00648;&#x00628; &#x00623;&#x00641;&#x00631;&#x0064a;&#x00642;&#x0064a;&#x00627;. </p></sec><sec><title>&#x00627;&#x00644;&#x00637;&#x00631;&#x0064a;&#x00642;&#x00629; </title><p>&#x0064a;&#x00645;&#x0062b;&#x00644; Xpert&#x000ae; MTB/RIF (&#x00648;&#x00627;&#x00644;&#x00645;&#x00639;&#x00631;&#x00648;&#x00641; &#x00627;&#x0062e;&#x0062a;&#x00635;&#x00627;&#x00631;&#x0064b;&#x00627; &#x00628;&#x00627;&#x00633;&#x00645; Xpert&#x000ae;&#x0200e;) &#x00641;&#x0062d;&#x00635;&#x0064b;&#x00627; &#x00622;&#x00644;&#x0064a;&#x0064b;&#x00627; &#x00642;&#x00627;&#x00626;&#x00645;&#x0064b;&#x00627; &#x00639;&#x00644;&#x00649; &#x0062a;&#x00641;&#x00627;&#x00639;&#x00644; &#x00627;&#x00644;&#x00628;&#x00648;&#x00644;&#x0064a;&#x00645;&#x0064a;&#x00631;&#x00627;&#x00632; &#x00627;&#x00644;&#x00645;&#x0062a;&#x00633;&#x00644;&#x00633;&#x00644;&#x0060c; &#x0062a;&#x00645; &#x00646;&#x00634;&#x00631;&#x00647; &#x00641;&#x0064a; &#x00627;&#x00644;&#x00641;&#x0062a;&#x00631;&#x00629; &#x00645;&#x00627; &#x00628;&#x0064a;&#x00646; &#x00639;&#x00627;&#x00645;&#x0064a; 2011 &#x00648;2013. &#x00648;&#x00643;&#x00627;&#x00646;&#x0062a; &#x00627;&#x00644;&#x00628;&#x0064a;&#x00627;&#x00646;&#x00627;&#x0062a; &#x00645;&#x0062a;&#x00627;&#x0062d;&#x00629; &#x00639;&#x00646; 102,007 &#x00645;&#x00646; &#x00627;&#x00644;&#x00628;&#x00627;&#x00644;&#x0063a;&#x0064a;&#x00646; &#x00627;&#x00644;&#x00630;&#x0064a;&#x00646; &#x0062a;&#x00645; &#x00639;&#x00644;&#x00627;&#x0062c;&#x00647;&#x00645; &#x00645;&#x00646; &#x00627;&#x00644;&#x00633;&#x00644; &#x00627;&#x00644;&#x00631;&#x00626;&#x00648;&#x0064a; &#x00641;&#x0064a; &#x00627;&#x00644;&#x00641;&#x0062a;&#x00631;&#x00629; &#x00628;&#x0064a;&#x00646; &#x00639;&#x00627;&#x00645;&#x0064a; 2010 &#x00648;2014. &#x00648;&#x0062a;&#x00645; &#x0062d;&#x00633;&#x00627;&#x00628; &#x00645;&#x00639;&#x0062f;&#x00644;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00625;&#x00628;&#x00644;&#x00627;&#x0063a; &#x00639;&#x00646; &#x00627;&#x00644;&#x00633;&#x00644; &#x00644;&#x00643;&#x00644; &#x00634;&#x00631;&#x0064a;&#x0062d;&#x00629; &#x00633;&#x00643;&#x00627;&#x00646;&#x0064a;&#x00629; &#x0062a;&#x00628;&#x00644;&#x0063a; 100,000 &#x00646;&#x00633;&#x00645;&#x00629; &#x00639;&#x00646; &#x00643;&#x00644; &#x00633;&#x00646;&#x00629; &#x0062a;&#x00642;&#x00648;&#x0064a;&#x00645;&#x0064a;&#x00629;&#x0060c; &#x00648;&#x00639;&#x00646; &#x00643;&#x00644; &#x00633;&#x00646;&#x00629; &#x0062a;&#x00628;&#x00639;&#x0064b;&#x00627; &#x00644;&#x00639;&#x00645;&#x00644;&#x0064a;&#x00627;&#x0062a; &#x00637;&#x00631;&#x0062d; &#x00627;&#x00644;&#x00627;&#x0062e;&#x0062a;&#x00628;&#x00627;&#x00631; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x00645;&#x00633;&#x0062a;&#x00648;&#x00649; &#x00627;&#x00644;&#x00645;&#x0062d;&#x00644;&#x0064a;&#x0060c; &#x00648;&#x00628;&#x00634;&#x00643;&#x00644; &#x00639;&#x00627;&#x00645;&#x0060c; &#x00648;&#x00639;&#x00646; &#x00637;&#x00631;&#x0064a;&#x00642; &#x0062a;&#x00623;&#x00643;&#x0064a;&#x0062f; &#x00627;&#x00644;&#x00628;&#x00643;&#x0062a;&#x0064a;&#x00631;&#x0064a;&#x00627;. &#x0062a;&#x00645; &#x0062a;&#x00639;&#x00631;&#x0064a;&#x00641; &#x00627;&#x00644;&#x00639;&#x00644;&#x00627;&#x0062c; &#x00627;&#x00644;&#x0062a;&#x0062c;&#x00631;&#x0064a;&#x00628;&#x0064a; &#x00639;&#x00644;&#x00649; &#x00623;&#x00646;&#x00647; &#x00639;&#x00644;&#x00627;&#x0062c; &#x00645;&#x00642;&#x0062f;&#x00645; &#x0062f;&#x00648;&#x00646; &#x0062a;&#x00623;&#x00643;&#x0064a;&#x0062f; &#x00627;&#x00644;&#x00628;&#x00643;&#x0062a;&#x0064a;&#x00631;&#x0064a;&#x00627; &#x00628;&#x00627;&#x00633;&#x0062a;&#x0062e;&#x0062f;&#x00627;&#x00645; &#x00627;&#x0062e;&#x0062a;&#x00628;&#x00627;&#x00631; Xpert&#x000ae;&#x0200e;&#x0060c; &#x00623;&#x00648; &#x00627;&#x00644;&#x00641;&#x0062d;&#x00635; &#x00627;&#x00644;&#x00645;&#x0062c;&#x00647;&#x00631;&#x0064a; &#x00644;&#x00645;&#x00633;&#x0062d;&#x00629; &#x00627;&#x00644;&#x00628;&#x00644;&#x0063a;&#x00645;&#x0060c; &#x00623;&#x00648; &#x00645;&#x00633;&#x0062a;&#x00646;&#x00628;&#x0062a; &#x00627;&#x00644;&#x00628;&#x00644;&#x0063a;&#x00645;. </p></sec><sec><title>&#x00627;&#x00644;&#x00646;&#x0062a;&#x00627;&#x00626;&#x0062c; </title><p>&#x00628;&#x0064a;&#x00646; &#x00639;&#x00627;&#x00645;&#x0064a; 2010 &#x00648;2014&#x0060c; &#x00627;&#x00646;&#x0062e;&#x00641;&#x00636;&#x0062a; &#x00646;&#x00633;&#x00628;&#x00629; &#x0063a;&#x0064a;&#x00631; &#x00627;&#x00644;&#x00645;&#x00635;&#x00627;&#x00628;&#x0064a;&#x00646; &#x00628;&#x00641;&#x0064a;&#x00631;&#x00648;&#x00633; &#x00627;&#x00644;&#x00639;&#x00648;&#x00632; &#x00627;&#x00644;&#x00645;&#x00646;&#x00627;&#x00639;&#x0064a; &#x00627;&#x00644;&#x00628;&#x00634;&#x00631;&#x0064a; (HIV) &#x00627;&#x00644;&#x00630;&#x0064a;&#x00646; &#x0062a;&#x00644;&#x00642;&#x00648;&#x00627; &#x00639;&#x00644;&#x00627;&#x0062c;&#x0064b;&#x00627; &#x0062a;&#x0062c;&#x00631;&#x0064a;&#x00628;&#x0064a;&#x0064b;&#x00627; &#x00645;&#x00646; &#x00627;&#x00644;&#x00633;&#x00644; &#x00645;&#x00646; 23&#x0200f;&#x0066a; (2445/10,643) &#x00625;&#x00644;&#x00649; 11&#x0200f;&#x0066a; (1149/10,089)&#x0061b; &#x00648;&#x00641;&#x0064a;&#x00645;&#x00627; &#x0064a;&#x0062e;&#x00635; &#x00627;&#x00644;&#x00645;&#x00631;&#x00636;&#x00649; &#x00627;&#x00644;&#x00645;&#x00635;&#x00627;&#x00628;&#x0064a;&#x00646; &#x00628;&#x00641;&#x0064a;&#x00631;&#x00648;&#x00633; &#x00627;&#x00644;&#x00639;&#x00648;&#x00632; &#x00627;&#x00644;&#x00645;&#x00646;&#x00627;&#x00639;&#x0064a; &#x00627;&#x00644;&#x00628;&#x00634;&#x00631;&#x0064a; (HIV)&#x0060c; &#x00641;&#x00642;&#x00637; &#x00627;&#x00646;&#x0062e;&#x00641;&#x00636;&#x0062a; &#x00627;&#x00644;&#x00646;&#x00633;&#x00628;&#x00629; &#x00645;&#x00646; 42&#x0200f;&#x0066a; (4229/9985) &#x00625;&#x00644;&#x00649; 27&#x0200f;&#x0066a; (2364/8823). &#x00643;&#x00645;&#x00627; &#x00627;&#x00646;&#x0062e;&#x00641;&#x00636; &#x00627;&#x00644;&#x00645;&#x00639;&#x0062f;&#x00644; &#x00627;&#x00644;&#x00625;&#x0062c;&#x00645;&#x00627;&#x00644;&#x0064a; &#x00644;&#x00644;&#x00625;&#x00628;&#x00644;&#x00627;&#x0063a; &#x00639;&#x00646; &#x00627;&#x00644;&#x00633;&#x00644; &#x00628;&#x00646;&#x00633;&#x00628;&#x00629; &#x0200f;12&#x0200f;&#x0066a; &#x00648;&#x0200f;&#x0200f;19&#x0066a; &#x00628;&#x0064a;&#x00646; &#x00627;&#x00644;&#x00645;&#x00631;&#x00636;&#x00649; &#x0063a;&#x0064a;&#x00631; &#x00627;&#x00644;&#x00645;&#x00635;&#x00627;&#x00628;&#x0064a;&#x00646; &#x00628;&#x00641;&#x0064a;&#x00631;&#x00648;&#x00633; &#x00646;&#x00642;&#x00635; &#x00627;&#x00644;&#x00645;&#x00646;&#x00627;&#x00639;&#x00629; &#x00627;&#x00644;&#x00628;&#x00634;&#x00631;&#x0064a;&#x00629; &#x00648;&#x00643;&#x00630;&#x00644;&#x00643; &#x00628;&#x0064a;&#x00646; &#x00627;&#x00644;&#x00645;&#x00635;&#x00627;&#x00628;&#x0064a;&#x00646; &#x00628;&#x00627;&#x00644;&#x00641;&#x0064a;&#x00631;&#x00648;&#x00633; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x0062a;&#x00648;&#x00627;&#x00644;&#x0064a;&#x0061b; &#x00648;&#x00627;&#x00631;&#x0062a;&#x00641;&#x00639; &#x00645;&#x00639;&#x0062f;&#x00644; &#x00627;&#x00644;&#x0062d;&#x00627;&#x00644;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00645;&#x00624;&#x00643;&#x0062f;&#x00629; &#x00644;&#x00644;&#x00628;&#x00643;&#x0062a;&#x00631;&#x0064a;&#x00627; &#x00628;&#x00646;&#x00633;&#x00628;&#x00629; 1&#x0200f;&#x0066a; &#x00648;&#x0200f;3&#x0200f;&#x0066a; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x0062a;&#x00648;&#x00627;&#x00644;&#x0064a;&#x0060c; &#x00643;&#x00645;&#x00627; &#x00627;&#x00646;&#x0062e;&#x00641;&#x00636; &#x00645;&#x00639;&#x0062f;&#x00644; &#x00627;&#x00644;&#x00639;&#x00644;&#x00627;&#x0062c; &#x00627;&#x00644;&#x0062a;&#x0062c;&#x00631;&#x0064a;&#x00628;&#x0064a; &#x00628;&#x00646;&#x00633;&#x00628;&#x00629; &#x0200f;56&#x0200f;&#x0066a; &#x00648;49&#x0200f;&#x0066a; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x0062a;&#x00648;&#x00627;&#x00644;&#x0064a;. &#x00638;&#x00647;&#x00631;&#x0062a; &#x00647;&#x00630;&#x00647; &#x00627;&#x00644;&#x0062a;&#x0063a;&#x0064a;&#x00631;&#x00627;&#x0062a; &#x0062a;&#x0062f;&#x00631;&#x0064a;&#x0062c;&#x0064a;&#x0064b;&#x00627; &#x00628;&#x00639;&#x0062f; &#x00637;&#x00631;&#x0062d; &#x00627;&#x00644;&#x00627;&#x0062e;&#x0062a;&#x00628;&#x00627;&#x00631; &#x00648;&#x0062b;&#x00628;&#x00627;&#x0062a;&#x00647; &#x00628;&#x00639;&#x0062f; 3 &#x00633;&#x00646;&#x00648;&#x00627;&#x0062a;. </p></sec><sec><title>&#x00627;&#x00644;&#x00627;&#x00633;&#x0062a;&#x00646;&#x0062a;&#x00627;&#x0062c; </title><p>&#x00627;&#x00631;&#x0062a;&#x00628;&#x00637; &#x00637;&#x00631;&#x0062d; &#x00627;&#x00644;&#x00627;&#x0062e;&#x0062a;&#x00628;&#x00627;&#x00631; &#x00627;&#x00644;&#x00633;&#x00631;&#x0064a;&#x00639; &#x00641;&#x0064a; &#x00628;&#x0064a;&#x00626;&#x00629; &#x00630;&#x00627;&#x0062a; &#x00645;&#x00639;&#x0062f;&#x00644; &#x00627;&#x00646;&#x0062a;&#x00634;&#x00627;&#x00631; &#x00645;&#x00631;&#x0062a;&#x00641;&#x00639; &#x00644;&#x00644;&#x00633;&#x00644; &#x00627;&#x00644;&#x00631;&#x00626;&#x00648;&#x0064a; &#x00648;&#x00639;&#x0062f;&#x00648;&#x00649; &#x00641;&#x0064a;&#x00631;&#x00648;&#x00633; &#x00627;&#x00644;&#x00639;&#x00648;&#x00632; &#x00627;&#x00644;&#x00645;&#x00646;&#x00627;&#x00639;&#x0064a; &#x00627;&#x00644;&#x00628;&#x00634;&#x00631;&#x0064a; (HIV) &#x00628;&#x0062e;&#x00641;&#x00636; &#x00627;&#x00644;&#x00639;&#x00644;&#x00627;&#x0062c; &#x00627;&#x00644;&#x0062a;&#x0062c;&#x00631;&#x0064a;&#x00628;&#x0064a; &#x00627;&#x00644;&#x00630;&#x0064a; &#x0062d;&#x0062f;&#x0062b; &#x0062a;&#x0062f;&#x00631;&#x0064a;&#x0062c;&#x0064a;&#x0064b;&#x00627; &#x00628;&#x00639;&#x0062f; &#x00627;&#x00633;&#x0062a;&#x00642;&#x0062f;&#x00627;&#x00645; &#x00627;&#x00644;&#x00627;&#x0062e;&#x0062a;&#x00628;&#x00627;&#x00631;&#x0060c; &#x00645;&#x00645;&#x00627; &#x0064a;&#x00639;&#x00643;&#x00633; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x00623;&#x00631;&#x0062c;&#x0062d; &#x00627;&#x00644;&#x00648;&#x00642;&#x0062a; &#x00627;&#x00644;&#x00644;&#x00627;&#x00632;&#x00645; &#x00644;&#x00644;&#x0062a;&#x00646;&#x00641;&#x0064a;&#x00630; &#x00627;&#x00644;&#x00643;&#x00627;&#x00645;&#x00644;. &#x00648;&#x00644;&#x00627; &#x0064a;&#x00632;&#x00627;&#x00644; &#x00623;&#x00643;&#x0062b;&#x00631; &#x00645;&#x00646; &#x00631;&#x00628;&#x00639; &#x00627;&#x00644;&#x00645;&#x00635;&#x00627;&#x00628;&#x0064a;&#x00646; &#x00628;&#x00641;&#x0064a;&#x00631;&#x00648;&#x00633; &#x00627;&#x00644;&#x00639;&#x00648;&#x00632; &#x00627;&#x00644;&#x00645;&#x00646;&#x00627;&#x00639;&#x0064a; &#x00627;&#x00644;&#x00628;&#x00634;&#x00631;&#x0064a; &#x00648;&#x00627;&#x00644;&#x00633;&#x00644; &#x0064a;&#x0062a;&#x00644;&#x00642;&#x00648;&#x00646; &#x00639;&#x00644;&#x00627;&#x0062c;&#x0064b;&#x00627; &#x0062a;&#x0062c;&#x00631;&#x0064a;&#x00628;&#x0064a;&#x0064b;&#x00627;&#x0060c; &#x00645;&#x00645;&#x00627; &#x0064a;&#x00633;&#x00644;&#x00637; &#x00627;&#x00644;&#x00636;&#x00648;&#x00621; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x0062a;&#x0062d;&#x0062f;&#x0064a; &#x00627;&#x00644;&#x0062a;&#x00634;&#x0062e;&#x0064a;&#x00635;&#x0064a; &#x00644;&#x0062f;&#x00649; &#x00647;&#x00624;&#x00644;&#x00627;&#x00621; &#x00627;&#x00644;&#x00645;&#x00631;&#x00636;&#x00649;. </p></sec></trans-abstract><trans-abstract xml:lang="zh"><title>&#x06458;&#x08981;</title><sec><title>&#x076ee;&#x07684;</title><p>&#x065e8;&#x05728;&#x08c03;&#x067e5;&#x05728;&#x05357;&#x0975e;&#x05f00;&#x0666e;&#x06566;&#x05f15;&#x08fdb;&#x04e00;&#x09879;&#x05feb;&#x0901f;&#x068c0;&#x06d4b;&#x04f5c;&#x04e3a;&#x0836f;&#x07269;&#x0654f;&#x0611f;&#x06027;&#x07ed3;&#x06838;&#x075c5;&#x04e00;&#x07ebf;&#x08bca;&#x065ad;&#x068c0;&#x06d4b;&#x065b9;&#x06cd5;&#x07684;&#x05f71;&#x054cd;&#x03002;</p></sec><sec><title>&#x065b9;&#x06cd5;</title><p>Xpert&#x000ae; MTB/RIF (Xpert&#x000ae;)&#x000a0;&#x0662f;&#x04e00;&#x09879;&#x057fa;&#x04e8e;&#x0805a;&#x05408;&#x09176;&#x094fe;&#x053cd;&#x05e94;&#x07684;&#x081ea;&#x052a8;&#x05206;&#x06790;&#x09879;&#x076ee;&#x0ff0c;&#x04e8e;&#x000a0;2011&#x000a0;&#x05e74;&#x081f3;&#x000a0;2013&#x000a0;&#x05e74;&#x095f4;&#x05f00;&#x05c55;&#x03002;&#x05206;&#x06790;&#x06570;&#x0636e;&#x053ef;&#x07528;&#x04e8e;&#x000a0;2010&#x000a0;&#x05e74;&#x081f3;&#x000a0;2014&#x000a0;&#x05e74;&#x095f4;&#x063a5;&#x053d7;&#x080ba;&#x07ed3;&#x06838;&#x075c5;&#x06cbb;&#x07597;&#x07684;&#x000a0;102&#x02009;007&#x000a0;&#x0540d;&#x06210;&#x04eba;&#x03002;&#x05206;&#x0522b;&#x09488;&#x05bf9;&#x05f00;&#x05c55;&#x07684;&#x05c40;&#x090e8;&#x06027;&#x068c0;&#x06d4b;&#x03001;&#x06574;&#x04f53;&#x06027;&#x068c0;&#x06d4b;&#x053ca;&#x07ecf;&#x07ec6;&#x083cc;&#x05b66;&#x08bc1;&#x05b9e;&#x07684;&#x068c0;&#x06d4b;&#x08ba1;&#x07b97;&#x04e86;&#x06bcf;&#x04e2a;&#x065e5;&#x05386;&#x05e74;&#x053ca;&#x06bcf;&#x05e74;&#x06bcf;&#x000a0;100&#x02009;000&#x000a0;&#x04eba;&#x053e3;&#x07684;&#x07ed3;&#x06838;&#x075c5;&#x05448;&#x062a5;&#x07387;&#x03002; &#x07ecf;&#x09a8c;&#x06027;&#x06cbb;&#x07597;&#x088ab;&#x05b9a;&#x04e49;&#x04e3a;&#x0672a;&#x07ecf;&#x08fc7;&#x000a0;Xpert&#x000ae;&#x000a0;&#x07ec6;&#x083cc;&#x05b66;&#x08bc1;&#x05b9e;&#x03001;&#x0672a;&#x08fdb;&#x0884c;&#x075f0;&#x06d82;&#x07247;&#x0955c;&#x068c0;&#x06216;&#x075f0;&#x057f9;&#x0517b;&#x07684;&#x07597;&#x06cd5;&#x03002;</p></sec><sec><title>&#x07ed3;&#x0679c;</title><p>&#x05728;&#x000a0;2010&#x000a0;&#x05e74;&#x081f3;&#x000a0;2014&#x000a0;&#x05e74;&#x095f4;&#x0ff0c;&#x063a5;&#x053d7;&#x07ed3;&#x06838;&#x075c5;&#x07ecf;&#x09a8c;&#x06027;&#x06cbb;&#x07597;&#x07684;&#x04eba;&#x07c7b;&#x0514d;&#x075ab;&#x07f3a;&#x09677;&#x075c5;&#x06bd2;&#x000a0;(HIV)-&#x09634;&#x06027;&#x060a3;&#x08005;&#x07684;&#x06bd4;&#x04f8b;&#x04ece;&#x000a0;23%&#x000a0;(2445/10&#x02009;643)&#x000a0;&#x0964d;&#x081f3;&#x000a0;11%&#x000a0;(1149/10&#x02009;089)&#x0ff1b;&#x05728;&#x000a0;HIV-&#x09634;&#x06027;&#x060a3;&#x08005;&#x04e2d;&#x0ff0c;&#x08be5;&#x06bd4;&#x04f8b;&#x04ece;&#x000a0;42%&#x000a0;(4229/9985)&#x000a0;&#x0964d;&#x081f3;&#x000a0;27%&#x000a0;(2364/8823)&#x03002; &#x0603b;&#x04f53;&#x0800c;&#x08a00;&#x0ff0c;HIV-&#x09634;&#x06027;&#x060a3;&#x08005;&#x0548c;&#x000a0;HIV-&#x09633;&#x06027;&#x060a3;&#x08005;&#x07684;&#x07ed3;&#x06838;&#x075c5;&#x05448;&#x062a5;&#x07387;&#x05206;&#x0522b;&#x0964d;&#x04f4e;&#x000a0;12%&#x000a0;&#x0548c;&#x000a0;19%&#x0ff1b;&#x07ecf;&#x07ec6;&#x083cc;&#x05b66;&#x08bc1;&#x05b9e;&#x07684;&#x075c5;&#x04f8b;&#x06bd4;&#x07387;&#x05206;&#x0522b;&#x0589e;&#x052a0;&#x000a0;1%&#x000a0;&#x0548c;&#x000a0;3%&#x0ff1b;&#x063a5;&#x053d7;&#x07ecf;&#x09a8c;&#x06027;&#x06cbb;&#x07597;&#x07684;&#x06bd4;&#x04f8b;&#x05206;&#x0522b;&#x0964d;&#x04f4e;&#x000a0;56%&#x000a0;&#x0548c;&#x000a0;49%&#x03002; &#x081ea;&#x08be5;&#x068c0;&#x06d4b;&#x065b9;&#x06cd5;&#x05f15;&#x08fdb;&#x04ee5;&#x06765;&#x0ff0c;&#x08fd9;&#x04e9b;&#x053d8;&#x05316;&#x09010;&#x06e10;&#x053d1;&#x0751f;&#x05e76;&#x05728;&#x000a0;3&#x000a0;&#x05e74;&#x0540e;&#x07a33;&#x05b9a;&#x04e0b;&#x06765;&#x03002;</p></sec><sec><title>&#x07ed3;&#x08bba;</title><p>&#x05728;&#x080ba;&#x07ed3;&#x06838;&#x075c5;&#x0548c;&#x000a0;HIV&#x000a0;&#x0611f;&#x067d3;&#x09ad8;&#x053d1;&#x05730;&#x0533a;&#x05f00;&#x05c55;&#x05feb;&#x0901f;&#x068c0;&#x06d4b;&#x05bfc;&#x081f4;&#x05f15;&#x08fdb;&#x08be5;&#x068c0;&#x06d4b;&#x0540e;&#x07ecf;&#x09a8c;&#x06027;&#x06cbb;&#x07597;&#x09010;&#x06e10;&#x051cf;&#x05c11;&#x04e86;&#x04e00;&#x0534a;&#x0ff0c;&#x08fd9;&#x053ef;&#x080fd;&#x053cd;&#x06620;&#x051fa;&#x05168;&#x09762;&#x063a8;&#x0884c;&#x08be5;&#x09879;&#x068c0;&#x06d4b;&#x06240;&#x09700;&#x07684;&#x065f6;&#x095f4;&#x03002; &#x08d85;&#x08fc7;&#x056db;&#x05206;&#x04e4b;&#x04e00;&#x07684;&#x000a0;HIV-&#x09633;&#x06027;&#x07ed3;&#x06838;&#x075c5;&#x060a3;&#x08005;&#x04ecd;&#x05728;&#x063a5;&#x053d7;&#x07ecf;&#x09a8c;&#x08bc1;&#x06cbb;&#x07597;&#x0ff0c;&#x08fd9;&#x051f8;&#x0663e;&#x04e86;&#x08fd9;&#x04e9b;&#x060a3;&#x08005;&#x09762;&#x04e34;&#x07684;&#x08bca;&#x065ad;&#x065b9;&#x09762;&#x07684;&#x06311;&#x06218;&#x03002;</p></sec></trans-abstract><trans-abstract xml:lang="ru"><title>&#x00420;&#x00435;&#x00437;&#x0044e;&#x0043c;&#x00435;</title><sec><title>&#x00426;&#x00435;&#x0043b;&#x0044c;</title><p>&#x00418;&#x00437;&#x00443;&#x00447;&#x00438;&#x00442;&#x0044c; &#x00432;&#x0043b;&#x00438;&#x0044f;&#x0043d;&#x00438;&#x00435; &#x00432;&#x00432;&#x00435;&#x00434;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x0044d;&#x0043a;&#x00441;&#x0043f;&#x00440;&#x00435;&#x00441;&#x00441;-&#x0043c;&#x00435;&#x00442;&#x0043e;&#x00434;&#x00430; &#x00432; &#x0043a;&#x00430;&#x00447;&#x00435;&#x00441;&#x00442;&#x00432;&#x00435; &#x00434;&#x00438;&#x00430;&#x00433;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x0043e;&#x00433;&#x0043e; &#x00442;&#x00435;&#x00441;&#x00442;&#x00430; &#x0043f;&#x00435;&#x00440;&#x00432;&#x0043e;&#x00439; &#x0043b;&#x00438;&#x0043d;&#x00438;&#x00438; &#x0043d;&#x00430; &#x00447;&#x00443;&#x00432;&#x00441;&#x00442;&#x00432;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x00439; &#x0043a; &#x0043b;&#x00435;&#x0043a;&#x00430;&#x00440;&#x00441;&#x00442;&#x00432;&#x00435;&#x0043d;&#x0043d;&#x0044b;&#x0043c; &#x00441;&#x00440;&#x00435;&#x00434;&#x00441;&#x00442;&#x00432;&#x00430;&#x0043c; &#x00442;&#x00443;&#x00431;&#x00435;&#x00440;&#x0043a;&#x00443;&#x0043b;&#x00435;&#x00437; &#x00432; &#x0041a;&#x00435;&#x00439;&#x0043f;&#x00442;&#x00430;&#x00443;&#x0043d;&#x00435;, &#x0042e;&#x00436;&#x0043d;&#x00430;&#x0044f; &#x00410;&#x00444;&#x00440;&#x00438;&#x0043a;&#x00430;.</p></sec><sec><title>&#x0041c;&#x00435;&#x00442;&#x0043e;&#x00434;&#x0044b;</title><p>Xpert&#x000ae; MTB/RIF&#x000a0;(Xpert&#x000ae;), &#x00430;&#x00432;&#x00442;&#x0043e;&#x0043c;&#x00430;&#x00442;&#x00438;&#x00437;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x00439; &#x00430;&#x0043d;&#x00430;&#x0043b;&#x00438;&#x00437; &#x0043d;&#x00430; &#x0043e;&#x00441;&#x0043d;&#x0043e;&#x00432;&#x00435; &#x0043f;&#x0043e;&#x0043b;&#x00438;&#x0043c;&#x00435;&#x00440;&#x00430;&#x00437;&#x0043d;&#x0043e;&#x00439; &#x00446;&#x00435;&#x0043f;&#x0043d;&#x0043e;&#x00439; &#x00440;&#x00435;&#x00430;&#x0043a;&#x00446;&#x00438;&#x00438;, &#x0043a;&#x0043e;&#x00442;&#x0043e;&#x00440;&#x0044b;&#x00439; &#x00431;&#x0044b;&#x0043b; &#x00432;&#x00432;&#x00435;&#x00434;&#x00435;&#x0043d; &#x00432; &#x0043f;&#x00435;&#x00440;&#x00438;&#x0043e;&#x00434; &#x0043c;&#x00435;&#x00436;&#x00434;&#x00443; 2011 &#x00438; 2013&#x000a0;&#x00433;&#x0043e;&#x00434;&#x00430;&#x0043c;&#x00438;. &#x00418;&#x0043c;&#x00435;&#x0043b;&#x00438;&#x00441;&#x0044c; &#x00434;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x00435;, &#x0043f;&#x0043e;&#x0043b;&#x00443;&#x00447;&#x00435;&#x0043d;&#x0043d;&#x0044b;&#x00435; &#x0043e;&#x00442; 102&#x000a0;007&#x000a0;&#x00432;&#x00437;&#x00440;&#x0043e;&#x00441;&#x0043b;&#x0044b;&#x00445; &#x0043f;&#x00430;&#x00446;&#x00438;&#x00435;&#x0043d;&#x00442;&#x0043e;&#x00432;, &#x0043a;&#x0043e;&#x00442;&#x0043e;&#x00440;&#x0044b;&#x00435; &#x0043b;&#x00435;&#x00447;&#x00438;&#x0043b;&#x00438;&#x00441;&#x0044c; &#x0043e;&#x00442; &#x00442;&#x00443;&#x00431;&#x00435;&#x00440;&#x0043a;&#x00443;&#x0043b;&#x00435;&#x00437;&#x00430; &#x0043b;&#x00435;&#x00433;&#x0043a;&#x00438;&#x00445; &#x00432; &#x0043f;&#x00435;&#x00440;&#x00438;&#x0043e;&#x00434; &#x00441; 2010 &#x0043f;&#x0043e; 2014&#x000a0;&#x00433;&#x0043e;&#x00434;. &#x0041f;&#x0043e;&#x0043a;&#x00430;&#x00437;&#x00430;&#x00442;&#x00435;&#x0043b;&#x0044c; &#x00440;&#x00435;&#x00433;&#x00438;&#x00441;&#x00442;&#x00440;&#x00438;&#x00440;&#x00443;&#x00435;&#x0043c;&#x0043e;&#x00439; &#x00437;&#x00430;&#x00431;&#x0043e;&#x0043b;&#x00435;&#x00432;&#x00430;&#x00435;&#x0043c;&#x0043e;&#x00441;&#x00442;&#x00438; &#x00442;&#x00443;&#x00431;&#x00435;&#x00440;&#x0043a;&#x00443;&#x0043b;&#x00435;&#x00437;&#x0043e;&#x0043c;&#x000a0;(&#x0043a;&#x0043e;&#x0043b;&#x00438;&#x00447;&#x00435;&#x00441;&#x00442;&#x00432;&#x0043e; &#x00441;&#x0043b;&#x00443;&#x00447;&#x00430;&#x00435;&#x00432; &#x0043d;&#x00430; 100&#x000a0;000&#x000a0;&#x00447;&#x00435;&#x0043b;&#x0043e;&#x00432;&#x00435;&#x0043a;) &#x00431;&#x0044b;&#x0043b; &#x00440;&#x00430;&#x00441;&#x00441;&#x00447;&#x00438;&#x00442;&#x00430;&#x0043d; &#x00434;&#x0043b;&#x0044f; &#x0043a;&#x00430;&#x00436;&#x00434;&#x0043e;&#x00433;&#x0043e; &#x0043a;&#x00430;&#x0043b;&#x00435;&#x0043d;&#x00434;&#x00430;&#x00440;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x00433;&#x0043e;&#x00434;&#x00430;, &#x00430; &#x00442;&#x00430;&#x0043a;&#x00436;&#x00435; &#x00434;&#x0043b;&#x0044f; &#x0043a;&#x00430;&#x00436;&#x00434;&#x0043e;&#x00433;&#x0043e; &#x00433;&#x0043e;&#x00434;&#x00430; &#x0043e;&#x00442;&#x0043d;&#x0043e;&#x00441;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0043e; &#x00432;&#x00432;&#x00435;&#x00434;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00442;&#x00435;&#x00441;&#x00442;&#x00430; &#x0043d;&#x00430; &#x0043c;&#x00435;&#x00441;&#x00442;&#x0043d;&#x0043e;&#x0043c; &#x00443;&#x00440;&#x0043e;&#x00432;&#x0043d;&#x00435; &#x00432; &#x00446;&#x00435;&#x0043b;&#x0043e;&#x0043c; &#x00438; &#x00441; &#x0043f;&#x0043e;&#x0043c;&#x0043e;&#x00449;&#x0044c;&#x0044e; &#x00431;&#x00430;&#x0043a;&#x00442;&#x00435;&#x00440;&#x00438;&#x0043e;&#x0043b;&#x0043e;&#x00433;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x0043e;&#x00433;&#x0043e; &#x0043f;&#x0043e;&#x00434;&#x00442;&#x00432;&#x00435;&#x00440;&#x00436;&#x00434;&#x00435;&#x0043d;&#x00438;&#x0044f;. &#x0042d;&#x0043c;&#x0043f;&#x00438;&#x00440;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x0043e;&#x00435; &#x0043b;&#x00435;&#x00447;&#x00435;&#x0043d;&#x00438;&#x00435; &#x0043e;&#x0043f;&#x00440;&#x00435;&#x00434;&#x00435;&#x0043b;&#x0044f;&#x0043b;&#x00438; &#x0043a;&#x00430;&#x0043a; &#x0043b;&#x00435;&#x00447;&#x00435;&#x0043d;&#x00438;&#x00435;, &#x0043f;&#x00440;&#x0043e;&#x00432;&#x0043e;&#x00434;&#x00438;&#x0043c;&#x0043e;&#x00435; &#x00431;&#x00435;&#x00437; &#x00431;&#x00430;&#x0043a;&#x00442;&#x00435;&#x00440;&#x00438;&#x0043e;&#x0043b;&#x0043e;&#x00433;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x0043e;&#x00433;&#x0043e; &#x0043f;&#x0043e;&#x00434;&#x00442;&#x00432;&#x00435;&#x00440;&#x00436;&#x00434;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00441; &#x0043f;&#x0043e;&#x0043c;&#x0043e;&#x00449;&#x0044c;&#x0044e; Xpert&#x000ae;, &#x0043c;&#x00438;&#x0043a;&#x00440;&#x0043e;&#x00441;&#x0043a;&#x0043e;&#x0043f;&#x00438;&#x00438; &#x0043c;&#x00430;&#x00437;&#x0043a;&#x00430; &#x0043c;&#x0043e;&#x0043a;&#x00440;&#x0043e;&#x00442;&#x0044b; &#x00438;&#x0043b;&#x00438; &#x00431;&#x00430;&#x0043a;&#x00442;&#x00435;&#x00440;&#x00438;&#x0043e;&#x0043b;&#x0043e;&#x00433;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x0043e;&#x00433;&#x0043e; &#x00438;&#x00441;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f; &#x0043c;&#x0043e;&#x0043a;&#x00440;&#x0043e;&#x00442;&#x0044b;.</p></sec><sec><title>&#x00420;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442;&#x0044b;</title><p>&#x00412; &#x0043f;&#x00435;&#x00440;&#x00438;&#x0043e;&#x00434; &#x0043c;&#x00435;&#x00436;&#x00434;&#x00443; 2010 &#x00438; 2014&#x000a0;&#x00433;&#x0043e;&#x00434;&#x00430;&#x0043c;&#x00438; &#x00434;&#x0043e;&#x0043b;&#x0044f; &#x00412;&#x00418;&#x00427;-&#x0043e;&#x00442;&#x00440;&#x00438;&#x00446;&#x00430;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x00445;&#x000a0;(&#x00412;&#x00418;&#x00427;&#x000a0;&#x02014; &#x00432;&#x00438;&#x00440;&#x00443;&#x00441; &#x00438;&#x0043c;&#x0043c;&#x00443;&#x0043d;&#x0043e;&#x00434;&#x00435;&#x00444;&#x00438;&#x00446;&#x00438;&#x00442;&#x00430; &#x00447;&#x00435;&#x0043b;&#x0043e;&#x00432;&#x00435;&#x0043a;&#x00430;) &#x0043f;&#x00430;&#x00446;&#x00438;&#x00435;&#x0043d;&#x00442;&#x0043e;&#x00432;, &#x0043f;&#x0043e;&#x0043b;&#x00443;&#x00447;&#x00430;&#x00432;&#x00448;&#x00438;&#x00445; &#x0044d;&#x0043c;&#x0043f;&#x00438;&#x00440;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x00443;&#x0044e; &#x00442;&#x00435;&#x00440;&#x00430;&#x0043f;&#x00438;&#x0044e; &#x0043f;&#x00440;&#x00438; &#x00442;&#x00443;&#x00431;&#x00435;&#x00440;&#x0043a;&#x00443;&#x0043b;&#x00435;&#x00437;&#x00435;, &#x00441;&#x0043d;&#x00438;&#x00437;&#x00438;&#x0043b;&#x00430;&#x00441;&#x0044c; &#x00441; 23%&#x000a0;(2445/10&#x000a0;643) &#x00434;&#x0043e; 11%&#x000a0;(1149/10&#x000a0;089), &#x00443; &#x00412;&#x00418;&#x00427;-&#x0043f;&#x0043e;&#x0043b;&#x0043e;&#x00436;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x00445; &#x0043f;&#x00430;&#x00446;&#x00438;&#x00435;&#x0043d;&#x00442;&#x0043e;&#x00432; &#x0044d;&#x00442;&#x0043e;&#x00442; &#x0043f;&#x0043e;&#x0043a;&#x00430;&#x00437;&#x00430;&#x00442;&#x00435;&#x0043b;&#x0044c; &#x00441;&#x0043d;&#x00438;&#x00437;&#x00438;&#x0043b;&#x00441;&#x0044f; &#x00441; 42%&#x000a0;(4229/9985) &#x00434;&#x0043e; 27%&#x000a0;(2364/8823). &#x0041e;&#x00431;&#x00449;&#x00438;&#x00439; &#x00443;&#x00440;&#x0043e;&#x00432;&#x00435;&#x0043d;&#x0044c; &#x00437;&#x00430;&#x00431;&#x0043e;&#x0043b;&#x00435;&#x00432;&#x00430;&#x00435;&#x0043c;&#x0043e;&#x00441;&#x00442;&#x00438; &#x00442;&#x00443;&#x00431;&#x00435;&#x00440;&#x0043a;&#x00443;&#x0043b;&#x00435;&#x00437;&#x0043e;&#x0043c; &#x00441;&#x0043d;&#x00438;&#x00437;&#x00438;&#x0043b;&#x00441;&#x0044f; &#x0043d;&#x00430; 12 &#x00438; 19% &#x00441;&#x00440;&#x00435;&#x00434;&#x00438; &#x00412;&#x00418;&#x00427;-&#x0043e;&#x00442;&#x00440;&#x00438;&#x00446;&#x00430;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x00445; &#x00438; &#x00412;&#x00418;&#x00427;-&#x0043f;&#x0043e;&#x0043b;&#x0043e;&#x00436;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x00445; &#x0043f;&#x00430;&#x00446;&#x00438;&#x00435;&#x0043d;&#x00442;&#x0043e;&#x00432; &#x00441;&#x0043e;&#x0043e;&#x00442;&#x00432;&#x00435;&#x00442;&#x00441;&#x00442;&#x00432;&#x00435;&#x0043d;&#x0043d;&#x0043e;, &#x00447;&#x00430;&#x00441;&#x00442;&#x0043e;&#x00442;&#x00430; &#x00431;&#x00430;&#x0043a;&#x00442;&#x00435;&#x00440;&#x00438;&#x0043e;&#x0043b;&#x0043e;&#x00433;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x00438; &#x0043f;&#x0043e;&#x00434;&#x00442;&#x00432;&#x00435;&#x00440;&#x00436;&#x00434;&#x00435;&#x0043d;&#x0043d;&#x0044b;&#x00445; &#x00441;&#x0043b;&#x00443;&#x00447;&#x00430;&#x00435;&#x00432; &#x00437;&#x00430;&#x00431;&#x0043e;&#x0043b;&#x00435;&#x00432;&#x00430;&#x00435;&#x0043c;&#x0043e;&#x00441;&#x00442;&#x00438; &#x00443;&#x00432;&#x00435;&#x0043b;&#x00438;&#x00447;&#x00438;&#x0043b;&#x00430;&#x00441;&#x0044c; &#x0043d;&#x00430; 1 &#x00438; 3% &#x00441;&#x0043e;&#x0043e;&#x00442;&#x00432;&#x00435;&#x00442;&#x00441;&#x00442;&#x00432;&#x00435;&#x0043d;&#x0043d;&#x0043e;, &#x00438; &#x00447;&#x00430;&#x00441;&#x00442;&#x0043e;&#x00442;&#x00430; &#x0043f;&#x00440;&#x00438;&#x0043c;&#x00435;&#x0043d;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x0044d;&#x0043c;&#x0043f;&#x00438;&#x00440;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x0043e;&#x00433;&#x0043e; &#x0043b;&#x00435;&#x00447;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00441;&#x0043d;&#x00438;&#x00437;&#x00438;&#x0043b;&#x00430;&#x00441;&#x0044c; &#x0043d;&#x00430; 56 &#x00438; 49% &#x00441;&#x0043e;&#x0043e;&#x00442;&#x00432;&#x00435;&#x00442;&#x00441;&#x00442;&#x00432;&#x00435;&#x0043d;&#x0043d;&#x0043e;. &#x0042d;&#x00442;&#x00438; &#x00438;&#x00437;&#x0043c;&#x00435;&#x0043d;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x0043f;&#x00440;&#x0043e;&#x00438;&#x00441;&#x00445;&#x0043e;&#x00434;&#x00438;&#x0043b;&#x00438; &#x0043f;&#x0043e;&#x00441;&#x00442;&#x00435;&#x0043f;&#x00435;&#x0043d;&#x0043d;&#x0043e; &#x0043f;&#x0043e;&#x00441;&#x0043b;&#x00435; &#x00432;&#x00432;&#x00435;&#x00434;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00442;&#x00435;&#x00441;&#x00442;&#x00430; &#x00438; &#x00441;&#x00442;&#x00430;&#x00431;&#x00438;&#x0043b;&#x00438;&#x00437;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043b;&#x00438;&#x00441;&#x0044c; &#x00447;&#x00435;&#x00440;&#x00435;&#x00437; 3&#x000a0;&#x00433;&#x0043e;&#x00434;&#x00430;.</p></sec><sec><title>&#x00412;&#x0044b;&#x00432;&#x0043e;&#x00434;</title><p>&#x00412;&#x00432;&#x00435;&#x00434;&#x00435;&#x0043d;&#x00438;&#x00435; &#x0044d;&#x0043a;&#x00441;&#x0043f;&#x00440;&#x00435;&#x00441;&#x00441;-&#x00442;&#x00435;&#x00441;&#x00442;&#x00430; &#x00432; &#x00443;&#x00441;&#x0043b;&#x0043e;&#x00432;&#x00438;&#x0044f;&#x00445; &#x00432;&#x0044b;&#x00441;&#x0043e;&#x0043a;&#x0043e;&#x00439; &#x00440;&#x00430;&#x00441;&#x0043f;&#x00440;&#x0043e;&#x00441;&#x00442;&#x00440;&#x00430;&#x0043d;&#x00435;&#x0043d;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x00438; &#x00442;&#x00443;&#x00431;&#x00435;&#x00440;&#x0043a;&#x00443;&#x0043b;&#x00435;&#x00437;&#x00430; &#x0043b;&#x00435;&#x00433;&#x0043a;&#x00438;&#x00445; &#x00438; &#x00412;&#x00418;&#x00427;-&#x00438;&#x0043d;&#x00444;&#x00435;&#x0043a;&#x00446;&#x00438;&#x00438; &#x00431;&#x0044b;&#x0043b;&#x0043e; &#x00441;&#x00432;&#x0044f;&#x00437;&#x00430;&#x0043d;&#x0043e; &#x00441; &#x00434;&#x00432;&#x00443;&#x0043a;&#x00440;&#x00430;&#x00442;&#x0043d;&#x0044b;&#x0043c; &#x00441;&#x0043e;&#x0043a;&#x00440;&#x00430;&#x00449;&#x00435;&#x0043d;&#x00438;&#x00435;&#x0043c; &#x0043f;&#x00440;&#x00438;&#x0043c;&#x00435;&#x0043d;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x0044d;&#x0043c;&#x0043f;&#x00438;&#x00440;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x0043e;&#x00433;&#x0043e; &#x0043b;&#x00435;&#x00447;&#x00435;&#x0043d;&#x00438;&#x0044f;, &#x0043a;&#x0043e;&#x00442;&#x0043e;&#x00440;&#x0043e;&#x00435; &#x0043f;&#x00440;&#x0043e;&#x00438;&#x00441;&#x00445;&#x0043e;&#x00434;&#x00438;&#x0043b;&#x0043e; &#x0043f;&#x0043e;&#x00441;&#x00442;&#x00435;&#x0043f;&#x00435;&#x0043d;&#x0043d;&#x0043e; &#x0043f;&#x0043e;&#x00441;&#x0043b;&#x00435; &#x00432;&#x00432;&#x00435;&#x00434;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00442;&#x00435;&#x00441;&#x00442;&#x00430;, &#x00447;&#x00442;&#x0043e;, &#x0043f;&#x0043e;-&#x00432;&#x00438;&#x00434;&#x00438;&#x0043c;&#x0043e;&#x0043c;&#x00443;, &#x0043e;&#x00442;&#x00440;&#x00430;&#x00436;&#x00430;&#x00435;&#x00442; &#x00432;&#x00440;&#x00435;&#x0043c;&#x0044f;, &#x0043d;&#x00435;&#x0043e;&#x00431;&#x00445;&#x0043e;&#x00434;&#x00438;&#x0043c;&#x0043e;&#x00435; &#x00434;&#x0043b;&#x0044f; &#x0043f;&#x0043e;&#x0043b;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x00432;&#x0043d;&#x00435;&#x00434;&#x00440;&#x00435;&#x0043d;&#x00438;&#x0044f;. &#x00411;&#x0043e;&#x0043b;&#x00435;&#x00435; &#x00447;&#x00435;&#x00442;&#x00432;&#x00435;&#x00440;&#x00442;&#x00438; &#x00412;&#x00418;&#x00427;-&#x0043f;&#x0043e;&#x0043b;&#x0043e;&#x00436;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x00445; &#x0043f;&#x00430;&#x00446;&#x00438;&#x00435;&#x0043d;&#x00442;&#x0043e;&#x00432; &#x00441; &#x00442;&#x00443;&#x00431;&#x00435;&#x00440;&#x0043a;&#x00443;&#x0043b;&#x00435;&#x00437;&#x0043e;&#x0043c; &#x0043f;&#x0043e;-&#x0043f;&#x00440;&#x00435;&#x00436;&#x0043d;&#x00435;&#x0043c;&#x00443; &#x0043b;&#x00435;&#x00447;&#x00438;&#x0043b;&#x00438;&#x00441;&#x0044c; &#x0044d;&#x0043c;&#x0043f;&#x00438;&#x00440;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x00438;, &#x00447;&#x00442;&#x0043e; &#x0043f;&#x0043e;&#x00434;&#x00447;&#x00435;&#x00440;&#x0043a;&#x00438;&#x00432;&#x00430;&#x00435;&#x00442; &#x0043f;&#x00440;&#x0043e;&#x00431;&#x0043b;&#x00435;&#x0043c;&#x0044b; &#x00441; &#x00434;&#x00438;&#x00430;&#x00433;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x00438;&#x0043a;&#x0043e;&#x00439; &#x00443; &#x0044d;&#x00442;&#x00438;&#x00445; &#x0043f;&#x00430;&#x00446;&#x00438;&#x00435;&#x0043d;&#x00442;&#x0043e;&#x00432;.</p></sec></trans-abstract></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Sputum smear microscopy is traditionally the first-line diagnostic test for tuberculosis in countries without routine access to the gold standard: sputum culture. This approach is limited by low sensitivity, particularly among patients who test positive for the human immunodeficiency virus (HIV), and is associated with diagnostic delays, underdiagnosis and empirical treatment.<xref rid="R1" ref-type="bibr"><sup>1</sup></xref> The Xpert&#x000ae; MTB/RIF (Xpert&#x000ae;) test (Cepheid, Sunnyvale, United States of America) is an automated, cartridge-based, rapid molecular diagnostic test for <italic>Mycobacterium tuberculosis</italic> and its resistance to rifampicin.<xref rid="R2" ref-type="bibr"><sup>2</sup></xref> The test detects the <italic>rpoB</italic> gene of <italic>M. tuberculosis</italic>, including mutations that encode rifampicin resistance, using a real-time polymerase chain reaction and takes less than 2&#x000a0;hours. Because the test has higher sensitivity than smear microscopy (88% versus 65%, respectively),<xref rid="R3" ref-type="bibr"><sup>3</sup></xref> is rapid and has the ability to detect rifampicin resistance immediately, the World Health Organization (WHO) endorsed its use in resource-constrained settings in December 2010.<xref rid="R4" ref-type="bibr"><sup>4</sup></xref> By the end of 2014, concessionary pricing had led to widespread roll-out of the test in lower-income countries.<xref rid="R5" ref-type="bibr"><sup>5</sup></xref></p><p>In 2013, WHO identified understanding the impact of the Xpert&#x000ae; test on individual and public health outcomes as one of the top 10 research areas in tuberculosis.<xref rid="R6" ref-type="bibr"><sup>6</sup></xref> Modelling studies indicated the test would increase tuberculosis case-finding and that the resulting earlier treatment would improve outcomes, leading eventually to reductions in tuberculosis incidence and mortality.<xref rid="R7" ref-type="bibr"><sup>7</sup></xref><sup>&#x02013;</sup><xref rid="R9" ref-type="bibr"><sup>9</sup></xref> However, the four large randomized trials published to date failed to document these reductions.<xref rid="R10" ref-type="bibr"><sup>10</sup></xref><sup>&#x02013;</sup><xref rid="R13" ref-type="bibr"><sup>13</sup></xref> This failure may have been due to empirical treatment being replaced by bacteriologically confirmed treatment rather than to more patients being identified.<xref rid="R14" ref-type="bibr"><sup>14</sup></xref> Subsequently, when one of the original modelling papers was modified to align its results with one of the trials, the predicted decline in tuberculosis incidence decreased from 6% to 1.6%.<xref rid="R10" ref-type="bibr"><sup>10</sup></xref><sup>,</sup><xref rid="R15" ref-type="bibr"><sup>15</sup></xref> Modelling the effect of the test in India produced similar results.<xref rid="R16" ref-type="bibr"><sup>16</sup></xref></p><p>There is a need for more data on the impact of the Xpert&#x000ae; test in practice. In South Africa, roll-out of this test as the primary test in a new tuberculosis diagnostic algorithm started in March 2011 &#x02013; it was completed in Cape Town in February 2013.<xref rid="R17" ref-type="bibr"><sup>17</sup></xref> In this study, we evaluated the impact of the test roll-out in Cape Town on the diagnosis of patients with drug-sensitive tuberculosis, stratified by HIV status. We also analysed associated changes in the proportion of notified tuberculosis cases that were confirmed bacteriologically and examined risk factors for empirical treatment. Finally, we determined whether the changes observed increased with time following the introduction of the test.</p></sec><sec sec-type="methods"><title>Methods</title><p>The estimated population of Cape Town in 2011 was 3.7&#x000a0;million.<xref rid="R18" ref-type="bibr"><sup>18</sup></xref> The diagnosis and treatment of tuberculosis in the city was provided by 101 government primary-care clinics; tuberculosis treatment in private clinics was infrequent.<xref rid="R19" ref-type="bibr"><sup>19</sup></xref> The diagnosis of pulmonary tuberculosis was generally based on sputum smear microscopy, with sputum culture reserved for patients who remained symptomatic despite negative microscopy findings or who were being retreated. At all clinics, chest X-ray facilities were available, either on-site or through referral. Although the empirical treatment of tuberculosis based on symptoms and chest X-ray findings alone was discouraged, it was an accepted practice for patients who remained symptomatic despite negative microbiological findings.</p><p>The Xpert&#x000ae; test machines were installed in all laboratories in Cape Town between August 2011 and February 2013 and use of the test as the primary diagnostic test in the tuberculosis diagnostic algorithm for Western Cape Province was endorsed in a circular to all primary health-care clinics in January 2013.<xref rid="R17" ref-type="bibr"><sup>17</sup></xref> Two sputum samples were collected and submitted simultaneously to a laboratory &#x02013; one was for the rapid test. If a rifampicin-sensitive <italic>M. tuberculosis</italic> strain was detected, the second sample was used to determine the sputum smear status pretreatment and, thereby, helps identify smear conversion during follow-up. If a rifampicin-resistant strain was detected, the second sample was used for culture and for testing drug sensitivity. If the first sample from an HIV-infected patient tested negative, the second was used for culture. If the first sample from an HIV-negative patient tested negative, the second was discarded because of the test&#x02019;s higher sensitivity in these patients. When the test was introduced, the treatment regimen for previously treated patients was changed to that for new patients because rifampicin resistance could then be identified before treatment.<xref rid="R17" ref-type="bibr"><sup>17</sup></xref></p><p>Our population-based study covered 2010 to 2014: 2010 was the last full calendar year before the test roll-out began in Cape Town and 2014 was the first full calendar year after roll-out had been completed. We included all pulmonary tuberculosis patients aged 15&#x000a0;years or older who started treatment during that period. To avoid duplication, we excluded patients transferred between subdistricts. We used anonymized data from the City of Cape Town electronic tuberculosis register on the patients&#x02019; characteristics, microbiological test results, chest X-ray results, treatment initiation dates and treatment outcomes. Patients with drug-resistant tuberculosis were entered into a separate register and were not included in our evaluation.</p><p>We defined the primary method of diagnosis as either: (i)&#x000a0;the rapid test; (ii)&#x000a0;sputum smear microscopy; or (iii)&#x000a0;sputum culture &#x02013; if more than one test was positive, the primary method was the first test in this sequence. We defined bacteriological confirmation of infection as a positive result to one of these tests. Empirical treatment was defined as treatment given when no test was positive or no test was performed. In addition, patients who tested positive on sputum culture and negative on, or did not undergo, other tests were regarded as having started empirical treatment if their sputum sample was sent for culture after treatment initiation or up to 6&#x000a0;days before initiation (assuming that 7&#x000a0;days was the minimum time required for a positive sputum culture result).<xref rid="R20" ref-type="bibr"><sup>20</sup></xref> Treatment followed national guidelines and did not differ by method of diagnosis.<xref rid="R21" ref-type="bibr"><sup>21</sup></xref> Two definitions of time were used: the calendar year and the year relative to the time when the test was introduced in the diagnosing clinic. For the latter year, we identified the date on which the first test result was recorded for each clinic and used this date as the roll-out date for that clinic. Patients were then assigned to a year depending on when their treatment started relative to the test roll-out in their clinic: patients who initiated treatment in the 365&#x000a0;days before the roll-out date were assigned to year&#x000a0;0 and those who started treatment 1096 to 1460&#x000a0;days after the roll-out date were assigned to year&#x000a0;4; other patients were assigned to intermediate years accordingly (<xref ref-type="fig" rid="F1">Fig.&#x000a0;1</xref>). The patient was defined as HIV-positive at the time of tuberculosis treatment if the tuberculosis register recorded: (i)&#x000a0;a positive HIV serological test result; (ii)&#x000a0;treatment with antiretroviral therapy or co-trimoxazole; or (iii)&#x000a0;a CD4+ T-lymphocyte (CD4+ cell) count. The patient was HIV-negative if a negative HIV serological test result had been recorded. All other patients were regarded as having an unknown HIV status.</p><fig id="F1" fig-type="figure" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Calendar year and year relative to rapid diagnostic test roll-out, Cape Town, South Africa, 2010&#x02013;2014</p></caption><p>Notes: Patients who initiated tuberculosis treatment in the year before the Xpert&#x000ae; MTB/RIF test (Cepheid, Sunnyvale, United States of America) roll-out date for their clinic were assigned to year&#x000a0;0, those who started treatment in the first year after roll-out for their clinic were assigned to year&#x000a0;1 and so on up to year&#x000a0;4. The Xpert&#x000ae; MTB/RIF test was introduced gradually as the first-line diagnostic test at 101 clinics between August 2011 and February 2013.</p><graphic xlink:href="BLT.16.185314-F1"/></fig><sec><title>Statistical analysis</title><p>We used descriptive statistics to present data on patients&#x02019; demographic and clinical characteristics in each calendar year and on the primary method of diagnosis in each calendar year and in each year relative to the test roll-out. We calculated annual population disease rates by dividing the total number of bacteriologically confirmed and empirically treated pulmonary tuberculosis patients aged 15&#x000a0;years or older in a year by the mid-year estimate of the adult population in the study area.<xref rid="R22" ref-type="bibr"><sup>22</sup></xref> Rates were also stratified by bacteriological confirmation and HIV status. The size of the HIV-negative and HIV-positive adult population was derived using annual HIV prevalence estimates from the Actuarial Society of South Africa Western Cape AIDS demographic model.<xref rid="R23" ref-type="bibr"><sup>23</sup></xref> We also calculated population disease rates relative to the year of test roll-out, overall and stratified by bacteriological confirmation. We estimated the population size for each year relative to test roll-out as follows, taking year&#x000a0;2 as an example: we calculated the proportion of all patients in each calendar year who were in year&#x000a0;2 of roll-out (<xref ref-type="fig" rid="F1">Fig.&#x000a0;1</xref>) and multiplied this proportion by the estimated population for the corresponding calendar year. We then summed these estimates for all calendar years, which gave us the total estimated population for year&#x000a0;2 of roll-out.</p><p>Factors associated with empirical tuberculosis treatment, both overall and stratified by HIV status, were identified by multivariable logistic regression analysis. A priori risk factors included age, sex, HIV status, CD4+ cell count at the start of tuberculosis treatment, history of tuberculosis treatment, calendar year and year relative to test roll-out. Age, calendar year and year relative to test roll-out were included as either continuous or categorical variables based on the results of tests for departure from linearity. Because of the collinearity between our two-time variables, we used two separate multivariable logistic regression models &#x02013; one included the calendar year and the other included the year relative to test roll-out. We accounted for clustering at the clinic level by calculating robust standard errors. In addition, a sensitivity analysis was performed using random effects models that adjusted for clustering at the clinic level. We tested for changes over time in the odds of empirical treatment in years&#x000a0;2, 3 and 4 of test roll-out using a model that included only those years. All analyses were performed using Stata/IC version 13.0 (StataCorp. LP, College Station, USA) and Excel 2013 (Microsoft Corporation, Redmond, USA). The study was approved by the Human Research Ethics Committee at the University of Cape Town and by the City of Cape Town Health Department.</p></sec></sec><sec sec-type="results"><title>Results</title><p>In 2010, 21&#x02009;255 patients with pulmonary tuberculosis aged 15&#x000a0;years or older were treated in Cape Town. The number declined annually to 19&#x02009;174 in 2014, the year after the test roll-out was completed. <xref ref-type="table" rid="T1">Table&#x000a0;1</xref> shows the patients&#x02019; demographic and clinical characteristics in each calendar year: their mean age was 35&#x000a0;years, 57% (57&#x02009;664/102&#x02009;007) were male and 48% (47&#x02009;542/100&#x02009;021) were HIV-positive. The HIV status was reported in 98% (100&#x02009;021/102&#x02009;007) of the patients. The only characteristic that changed substantially over time was the proportion of patients previously treated for tuberculosis, which was lower in later years. By March 2012, 62% (63/101) of tuberculosis clinics had access to the test. There was no difference in patients&#x02019; demographic or clinical characteristics by either year relative to test roll-out or calendar year. Details of the patients covered by rapid testing in each year and their characteristics are available from the corresponding author on request.</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Patients&#x02019; characteristics, impact of the rapid diagnostic test roll-out on tuberculosis diagnosis, Cape Town, South Africa, 2010&#x02013;2014</title></caption><table frame="hsides" rules="groups"><col width="108" span="1"/><col width="66" span="1"/><col width="66" span="1"/><col width="66" span="1"/><col width="66" span="1"/><col width="66" span="1"/><thead><tr><th rowspan="3" valign="top" align="left" scope="col" colspan="1">Characteristic</th><th colspan="5" valign="top" align="center" scope="colgroup" rowspan="1">Number of patients (%)<sup>a</sup><hr/></th></tr><tr><th colspan="5" valign="top" align="center" scope="colgroup" rowspan="1">Calendar year<hr/></th></tr><tr><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">2010</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">2011</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">2012</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">2013</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">2014</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><bold>All</bold></td><td valign="top" align="center" rowspan="1" colspan="1">21&#x02009;255 </td><td valign="top" align="center" rowspan="1" colspan="1">20&#x02009;828 </td><td valign="top" align="center" rowspan="1" colspan="1">20&#x02009;657 </td><td valign="top" align="center" rowspan="1" colspan="1">20&#x02009;093 </td><td valign="top" align="center" rowspan="1" colspan="1">19&#x02009;174 </td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><bold>Female</bold></td><td valign="top" align="center" rowspan="1" colspan="1">9&#x000a0;602 (45)</td><td valign="top" align="center" rowspan="1" colspan="1">9&#x000a0;214 (44)</td><td valign="top" align="center" rowspan="1" colspan="1">8&#x000a0;883 (43)</td><td valign="top" align="center" rowspan="1" colspan="1">8&#x000a0;621 (43)</td><td valign="top" align="center" rowspan="1" colspan="1">8&#x000a0;023 (42)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Age in years</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">15&#x02013;24</td><td valign="top" align="center" rowspan="1" colspan="1">3&#x000a0;991 (19)</td><td valign="top" align="center" rowspan="1" colspan="1">3&#x000a0;728 (18)</td><td valign="top" align="center" rowspan="1" colspan="1">3&#x000a0;654 (18)</td><td valign="top" align="center" rowspan="1" colspan="1">3&#x000a0;487 (17)</td><td valign="top" align="center" rowspan="1" colspan="1">3&#x000a0;287 (17)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">25&#x02013;34</td><td valign="top" align="center" rowspan="1" colspan="1">7&#x000a0;099 (33)</td><td valign="top" align="center" rowspan="1" colspan="1">6&#x000a0;756 (32)</td><td valign="top" align="center" rowspan="1" colspan="1">6&#x000a0;574 (32)</td><td valign="top" align="center" rowspan="1" colspan="1">6&#x000a0;472 (32)</td><td valign="top" align="center" rowspan="1" colspan="1">6&#x000a0;046 (32)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">35&#x02013;44</td><td valign="top" align="center" rowspan="1" colspan="1">5&#x000a0;271 (25)</td><td valign="top" align="center" rowspan="1" colspan="1">5&#x000a0;461 (26)</td><td valign="top" align="center" rowspan="1" colspan="1">5&#x000a0;425 (26)</td><td valign="top" align="center" rowspan="1" colspan="1">5&#x000a0;315 (27)</td><td valign="top" align="center" rowspan="1" colspan="1">4&#x000a0;991 (26)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">45&#x02013;54</td><td valign="top" align="center" rowspan="1" colspan="1">3&#x000a0;202 (15)</td><td valign="top" align="center" rowspan="1" colspan="1">3&#x000a0;171 (15)</td><td valign="top" align="center" rowspan="1" colspan="1">3&#x000a0;236 (16)</td><td valign="top" align="center" rowspan="1" colspan="1">3&#x000a0;053 (15)</td><td valign="top" align="center" rowspan="1" colspan="1">3&#x000a0;130 (16)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">55&#x02013;64</td><td valign="top" align="center" rowspan="1" colspan="1">1&#x000a0;222 (6)</td><td valign="top" align="center" rowspan="1" colspan="1">1&#x000a0;235 (6)</td><td valign="top" align="center" rowspan="1" colspan="1">1&#x000a0;286 (6)</td><td valign="top" align="center" rowspan="1" colspan="1">1&#x000a0;249 (6)</td><td valign="top" align="center" rowspan="1" colspan="1">1&#x000a0;233 (6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02265;65</td><td valign="top" align="center" rowspan="1" colspan="1">470 (2)</td><td valign="top" align="center" rowspan="1" colspan="1">477 (2)</td><td valign="top" align="center" rowspan="1" colspan="1">482 (2)</td><td valign="top" align="center" rowspan="1" colspan="1">517 (3)</td><td valign="top" align="center" rowspan="1" colspan="1">487 (3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><bold>Previously treated for tuberculosis</bold></td><td valign="top" align="center" rowspan="1" colspan="1">6&#x000a0;626 (31)</td><td valign="top" align="center" rowspan="1" colspan="1">6&#x000a0;588 (32)</td><td valign="top" align="center" rowspan="1" colspan="1">6&#x000a0;714 (33)</td><td valign="top" align="center" rowspan="1" colspan="1">5&#x000a0;738 (29)</td><td valign="top" align="center" rowspan="1" colspan="1">4&#x000a0;864 (25)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><bold>HIV-positive<sup>b</sup></bold></td><td valign="top" align="center" rowspan="1" colspan="1">9&#x000a0;985 (48)</td><td valign="top" align="center" rowspan="1" colspan="1">9&#x000a0;922 (49)</td><td valign="top" align="center" rowspan="1" colspan="1">9&#x000a0;650 (48)</td><td valign="top" align="center" rowspan="1" colspan="1">9&#x000a0;162 (46)</td><td valign="top" align="center" rowspan="1" colspan="1">8&#x000a0;823 (47)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><bold>CD4+ T-lymphocyte count per mm<sup>3</sup>, median (IQR)<sup>c</sup></bold></td><td valign="top" align="center" rowspan="1" colspan="1">167 (77&#x02013;296)</td><td valign="top" align="center" rowspan="1" colspan="1">181 (83&#x02013;316)</td><td valign="top" align="center" rowspan="1" colspan="1">185 (80&#x02013;329)</td><td valign="top" align="center" rowspan="1" colspan="1">179 (75&#x02013;330)</td><td valign="top" align="center" rowspan="1" colspan="1">173 (73&#x02013;339)</td></tr></tbody></table><table-wrap-foot><p>HIV: human immunodeficiency virus; IQR: interquartile range; SD: standard deviation.</p><p><sup>a</sup> All values in the table represent absolute numbers and percentages unless otherwise stated.</p><p><sup>b</sup> The number of patients whose HIV status was unknown was 627 in 2010, 413 in 2011, 412 in 2012, 272 in 2013 and 262 in 2014.</p><p><sup>c</sup> The number of patients whose CD4+ T-lymphocyte count was unknown was 358 in 2010, 259 in 2011, 310 in 2012, 287 in 2013 and 584 in 2014.</p><p>Note: The roll-out of the automated Xpert&#x000ae; MTB/RIF test (Cepheid, Sunnyvale, United States of America) occurred between August 2011 and February 2013.</p></table-wrap-foot></table-wrap><p>The pattern of microbiological testing in patients with pulmonary tuberculosis changed during the test roll-out: use of this test increased to 88% (16&#x02009;892/19&#x02009;174) of patients in 2014, with 14&#x02009;551 of the 16&#x02009;892 (86%) testing positive. Correspondingly, utilization of sputum smear microscopy and sputum culture decreased. <xref ref-type="fig" rid="F2">Fig.&#x000a0;2</xref> shows that use of the test stabilized after the first 2&#x000a0;years of roll-out. Findings were similar among HIV-negative and HIV-positive patients (details available from the corresponding author on request).</p><fig id="F2" fig-type="figure" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Diagnostic tests for pulmonary tuberculosis, by year relative to rapid diagnostic test roll-out, Cape Town, South Africa, 2010&#x02013;2014</p></caption><p>Notes: Patients who initiated tuberculosis treatment in the year before the Xpert&#x000ae; MTB/RIF test (Cepheid, Sunnyvale, United States of America) roll-out date for their clinic were assigned to year&#x000a0;0, those who started treatment in the first year after roll-out for their clinic were assigned to year&#x000a0;1 and so on up to year&#x000a0;4 (<xref ref-type="fig" rid="F1">Fig.&#x000a0;1</xref>). The proportion of patients for whom only a sputum culture result was available was negligible.</p><graphic xlink:href="BLT.16.185314-F2"/></fig><p>The reasons for starting tuberculosis treatment changed over time: in 2010, the main reason was a positive sputum smear result in 67% (7100/10&#x02009;643) of HIV-negative patients and in 41% (4082/9985) of HIV-positive patients; in 2014, the main reason was a positive Xpert&#x000ae; test result in 84% (8431/10&#x02009;089) and 67% (5947/8823) of these patient groups, respectively (<xref ref-type="table" rid="T2">Table&#x000a0;2</xref>). Between 2010 and 2014, the proportion treated empirically decreased by 12&#x000a0;percentage points among HIV-negative patients and by 15&#x000a0;percentage points among HIV-positive patients. After excluding those for whom a positive sputum culture result became available after treatment initiation, the decrease in empirical treatment was 8&#x000a0;percentage points in both groups: among HIV-negative patients, the proportion decreased from 19% (2009/10&#x02009;643) in 2010 to 11% (1115/10&#x02009;089) in 2014; and, among HIV-positive patients, it decreased from 34% (3440/9985) to 26% (2293/8823). The proportion of patients with pulmonary tuberculosis diagnosed using the Xpert&#x000ae; test increased continuously during roll-out up to year&#x000a0;3 and stabilized thereafter (<xref ref-type="table" rid="T3">Table&#x000a0;3</xref>). The principal change underlying the decrease in empirical treatment during the study period was that fewer patients with a negative smear result were treated: among HIV-negative patients, 8% (800/10&#x02009;643) were treated despite a negative smear result in 2010 compared with 1% (36/10&#x02009;089) in 2014; among HIV-positive patients, the corresponding figures were 15% (1544/9985) and 1% (84/8823), respectively. In contrast, the proportion treated despite a negative Xpert&#x000ae; test result did not change substantially over time relative to test roll-out and the proportion treated because of abnormal chest X-ray findings alone decreased slightly among HIV-negative patients but did not change among HIV-positive patients, by both time definitions (details available from the corresponding author on request).</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Reason for tuberculosis treatment before, during and after the roll-out of a rapid diagnostic test for tuberculosis, Cape Town, South Africa, 2010&#x02013;2014</title></caption><table frame="hsides" rules="groups"><col width="118" span="1"/><col width="64" span="1"/><col width="64" span="1"/><col width="64" span="1"/><col width="64" span="1"/><col width="64" span="1"/><thead><tr><th rowspan="3" valign="top" align="left" scope="col" colspan="1">Reason for starting tuberculosis treatment</th><th colspan="5" valign="top" align="center" scope="colgroup" rowspan="1">Number of patients (%)<hr/></th></tr><tr><th colspan="5" valign="top" align="center" scope="colgroup" rowspan="1">Calendar year<hr/></th></tr><tr><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">2010</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">2011</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">2012</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">2013</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">2014</th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>HIV-negative patients</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Total<sup>a</sup></td><td valign="top" align="center" rowspan="1" colspan="1">10&#x02009;643</td><td valign="top" align="center" rowspan="1" colspan="1">10&#x02009;493</td><td valign="top" align="center" rowspan="1" colspan="1">10&#x02009;595</td><td valign="top" align="center" rowspan="1" colspan="1">10&#x02009;659</td><td valign="top" align="center" rowspan="1" colspan="1">10&#x02009;089</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Positive rapid test result</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">631 (6)</td><td valign="top" align="center" rowspan="1" colspan="1">3&#x000a0;954 (37)</td><td valign="top" align="center" rowspan="1" colspan="1">7&#x000a0;975 (75)</td><td valign="top" align="center" rowspan="1" colspan="1">8&#x000a0;431 (84)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Positive sputum smear</td><td valign="top" align="center" rowspan="1" colspan="1">7&#x000a0;100 (67)</td><td valign="top" align="center" rowspan="1" colspan="1">6&#x000a0;623 (63)</td><td valign="top" align="center" rowspan="1" colspan="1">4&#x000a0;040 (38)</td><td valign="top" align="center" rowspan="1" colspan="1">1&#x000a0;012 (9)</td><td valign="top" align="center" rowspan="1" colspan="1">452 (4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Positive sputum culture</td><td valign="top" align="center" rowspan="1" colspan="1">1&#x000a0;098 (10)</td><td valign="top" align="center" rowspan="1" colspan="1">994 (9)</td><td valign="top" align="center" rowspan="1" colspan="1">514 (5)</td><td valign="top" align="center" rowspan="1" colspan="1">144 (1)</td><td valign="top" align="center" rowspan="1" colspan="1">57 (1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Empirical treatment<sup>b</sup></td><td valign="top" align="center" rowspan="1" colspan="1">2&#x000a0;445 (23)</td><td valign="top" align="center" rowspan="1" colspan="1">2&#x000a0;245 (21)</td><td valign="top" align="center" rowspan="1" colspan="1">2&#x000a0;087 (20)</td><td valign="top" align="center" rowspan="1" colspan="1">1&#x000a0;528 (14)</td><td valign="top" align="center" rowspan="1" colspan="1">1&#x000a0;149 (11)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>HIV-positive patients</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Total<sup>a</sup></td><td valign="top" align="center" rowspan="1" colspan="1">9&#x000a0;985</td><td valign="top" align="center" rowspan="1" colspan="1">9&#x000a0;922</td><td valign="top" align="center" rowspan="1" colspan="1">9&#x000a0;650</td><td valign="top" align="center" rowspan="1" colspan="1">9&#x000a0;162</td><td valign="top" align="center" rowspan="1" colspan="1">8&#x000a0;823</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Positive rapid test result</td><td valign="top" align="center" rowspan="1" colspan="1">1 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">400 (4)</td><td valign="top" align="center" rowspan="1" colspan="1">2&#x000a0;906 (30)</td><td valign="top" align="center" rowspan="1" colspan="1">5&#x000a0;386 (59)</td><td valign="top" align="center" rowspan="1" colspan="1">5&#x000a0;947 (67)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Positive sputum smear</td><td valign="top" align="center" rowspan="1" colspan="1">4&#x000a0;082 (41)</td><td valign="top" align="center" rowspan="1" colspan="1">3&#x000a0;693 (37)</td><td valign="top" align="center" rowspan="1" colspan="1">2&#x000a0;290 (24)</td><td valign="top" align="center" rowspan="1" colspan="1">658 (7)</td><td valign="top" align="center" rowspan="1" colspan="1">248 (3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Positive sputum culture</td><td valign="top" align="center" rowspan="1" colspan="1">1&#x000a0;673 (17)</td><td valign="top" align="center" rowspan="1" colspan="1">1&#x000a0;643 (17)</td><td valign="top" align="center" rowspan="1" colspan="1">832 (9)</td><td valign="top" align="center" rowspan="1" colspan="1">320 (3)</td><td valign="top" align="center" rowspan="1" colspan="1">264 (3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Empirical treatment<sup>b</sup></td><td valign="top" align="center" rowspan="1" colspan="1">4&#x000a0;229 (42)</td><td valign="top" align="center" rowspan="1" colspan="1">4&#x000a0;186 (42)</td><td valign="top" align="center" rowspan="1" colspan="1">3&#x000a0;622 (38)</td><td valign="top" align="center" rowspan="1" colspan="1">2&#x000a0;798 (31)</td><td valign="top" align="center" rowspan="1" colspan="1">2&#x000a0;364 (27)</td></tr></tbody></table><table-wrap-foot><p>HIV: human immunodeficiency virus.</p><p><sup>a</sup> The number of patients whose HIV status was unknown was 627 in 2010, 413 in 2011, 412 in 2012, 272 in 2013 and 262 in 2014.</p><p><sup>b</sup> Treatment was empirical when no test gave a positive result or no test was performed.</p><p>Note: The roll-out of the automated Xpert&#x000ae; MTB/RIF test (Cepheid, Sunnyvale, United States of America) occurred between August 2011 and February 2013.</p></table-wrap-foot></table-wrap><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Reason for tuberculosis treatment, by year relative to the rapid diagnostic test roll-out, Cape Town, South Africa, 2010&#x02013;2014</title></caption><table frame="hsides" rules="groups"><col width="118" span="1"/><col width="64" span="1"/><col width="64" span="1"/><col width="64" span="1"/><col width="64" span="1"/><col width="64" span="1"/><thead><tr><th rowspan="3" valign="top" align="left" scope="col" colspan="1">Reason for starting tuberculosis treatment</th><th colspan="5" valign="top" align="center" scope="colgroup" rowspan="1">Number of patients (%)<hr/></th></tr><tr><th colspan="5" valign="top" align="center" scope="colgroup" rowspan="1">Year relative to rapid test roll-out<sup>a</sup><hr/></th></tr><tr><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">0</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">1</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">2</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">3</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">4</th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>HIV-negative patients</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Total<sup>b</sup></td><td valign="top" align="center" rowspan="1" colspan="1">10&#x02009;553</td><td valign="top" align="center" rowspan="1" colspan="1">10&#x02009;827</td><td valign="top" align="center" rowspan="1" colspan="1">10&#x02009;610</td><td valign="top" align="center" rowspan="1" colspan="1">7&#x000a0;207</td><td valign="top" align="center" rowspan="1" colspan="1">918</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Positive rapid test result</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">6&#x000a0;045 (56)</td><td valign="top" align="center" rowspan="1" colspan="1">8&#x000a0;141 (77)</td><td valign="top" align="center" rowspan="1" colspan="1">5&#x000a0;976 (83)</td><td valign="top" align="center" rowspan="1" colspan="1">766 (83)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Positive sputum smear</td><td valign="top" align="center" rowspan="1" colspan="1">7&#x000a0;189 (68)</td><td valign="top" align="center" rowspan="1" colspan="1">2&#x000a0;532 (23)</td><td valign="top" align="center" rowspan="1" colspan="1">888 (8)</td><td valign="top" align="center" rowspan="1" colspan="1">323 (4)</td><td valign="top" align="center" rowspan="1" colspan="1">29 (3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Positive sputum culture</td><td valign="top" align="center" rowspan="1" colspan="1">1&#x000a0;002 (9)</td><td valign="top" align="center" rowspan="1" colspan="1">372 (3)</td><td valign="top" align="center" rowspan="1" colspan="1">124 (1)</td><td valign="top" align="center" rowspan="1" colspan="1">37 (1)</td><td valign="top" align="center" rowspan="1" colspan="1">8 (1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Empirical treatment<sup>c</sup></td><td valign="top" align="center" rowspan="1" colspan="1">2&#x000a0;362 (22)</td><td valign="top" align="center" rowspan="1" colspan="1">1&#x000a0;878 (17)</td><td valign="top" align="center" rowspan="1" colspan="1">1&#x000a0;457 (14)</td><td valign="top" align="center" rowspan="1" colspan="1">871 (12)</td><td valign="top" align="center" rowspan="1" colspan="1">115 (13)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>HIV-positive patients</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Total<sup>b</sup></td><td valign="top" align="center" rowspan="1" colspan="1">9&#x000a0;848</td><td valign="top" align="center" rowspan="1" colspan="1">9&#x000a0;821</td><td valign="top" align="center" rowspan="1" colspan="1">9&#x000a0;138</td><td valign="top" align="center" rowspan="1" colspan="1">6&#x000a0;463</td><td valign="top" align="center" rowspan="1" colspan="1">936</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Positive rapid test result</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">4&#x000a0;177 (43)</td><td valign="top" align="center" rowspan="1" colspan="1">5&#x000a0;494 (60)</td><td valign="top" align="center" rowspan="1" colspan="1">4&#x000a0;297 (66)</td><td valign="top" align="center" rowspan="1" colspan="1">630 (67)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Positive sputum smear</td><td valign="top" align="center" rowspan="1" colspan="1">4&#x000a0;036 (41)</td><td valign="top" align="center" rowspan="1" colspan="1">1&#x000a0;619 (16)</td><td valign="top" align="center" rowspan="1" colspan="1">617 (7)</td><td valign="top" align="center" rowspan="1" colspan="1">165 (3)</td><td valign="top" align="center" rowspan="1" colspan="1">18 (2)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Positive sputum culture</td><td valign="top" align="center" rowspan="1" colspan="1">1&#x000a0;636 (17)</td><td valign="top" align="center" rowspan="1" colspan="1">726 (7)</td><td valign="top" align="center" rowspan="1" colspan="1">310 (3)</td><td valign="top" align="center" rowspan="1" colspan="1">165 (3)</td><td valign="top" align="center" rowspan="1" colspan="1">22 (2)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Empirical treatment<sup>c</sup></td><td valign="top" align="center" rowspan="1" colspan="1">4&#x000a0;176 (42)</td><td valign="top" align="center" rowspan="1" colspan="1">3&#x000a0;299 (34)</td><td valign="top" align="center" rowspan="1" colspan="1">2&#x000a0;717 (30)</td><td valign="top" align="center" rowspan="1" colspan="1">1&#x000a0;836 (28)</td><td valign="top" align="center" rowspan="1" colspan="1">266 (28)</td></tr></tbody></table><table-wrap-foot><p>HIV: human immunodeficiency virus.</p><p><sup>a</sup> Patients who initiated tuberculosis treatment in the year before the Xpert&#x000ae; MTB/RIF test roll-out date for their clinic were assigned to year&#x000a0;0, those who started treatment in the first year after roll-out for their clinic were assigned to year&#x000a0;1 and so on up to year&#x000a0;4 (<xref ref-type="fig" rid="F1">Fig.&#x000a0;1</xref>).</p><p><sup>b</sup> The number of patients whose HIV status was unknown was 627 in 2010, 413 in 2011, 412 in 2012, 272 in 2013 and 262 in 2014.</p><p><sup>c</sup> Treatment was empirical when no test gave a positive result or no test was performed.</p><p>Note: The roll-out of the automated Xpert&#x000ae; MTB/RIF test (Cepheid, Sunnyvale, United States of America) occurred between August 2011 and February 2013.</p></table-wrap-foot></table-wrap><p>The tuberculosis notification rate in the adult population decreased over the 5-year study period: by 12% among HIV-negative individuals and by 19% among HIV-positive individuals (<xref ref-type="fig" rid="F3">Fig.&#x000a0;3</xref> and <xref ref-type="fig" rid="F4">Fig.&#x000a0;4</xref>, respectively). The rate of bacteriologically confirmed tuberculosis increased by 1% and 3% in these two groups, respectively, and the rate of empirical treatment decreased by 56% and 49%, respectively. A slightly different pattern was seen when the data were analysed by year relative to test roll-out: the rate of bacteriologically confirmed tuberculosis increased between year&#x000a0;0 and year&#x000a0;4 by 7% in HIV-negative individuals (<xref ref-type="fig" rid="F5">Fig.&#x000a0;5</xref>) and by 17% in HIV-positive individuals (<xref ref-type="fig" rid="F6">Fig.&#x000a0;6</xref>), and the rate of empirical treatment decreased by 47% and 37%, respectively. These changes stabilized after year&#x000a0;3.</p><fig id="F3" fig-type="figure" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>Tuberculosis notification rates in HIV-negative patients, by calendar year, Cape Town, South Africa, 2010&#x02013;2014</p></caption><p>HIV: human immunodeficiency virus. </p><p>Note: Treatment was empirical when no test gave a positive result or no test was performed.</p><graphic xlink:href="BLT.16.185314-F3"/></fig><fig id="F4" fig-type="figure" orientation="portrait" position="float"><label>Fig. 4</label><caption><p>Tuberculosis notification rates in HIV-positive patients, by calendar year, Cape Town, South Africa, 2010&#x02013;2014</p></caption><p>HIV: human immunodeficiency virus.</p><p>Note: Treatment was empirical when no test gave a positive result or no test was performed.</p><graphic xlink:href="BLT.16.185314-F4"/></fig><fig id="F5" fig-type="figure" orientation="portrait" position="float"><label>Fig. 5</label><caption><p>Tuberculosis notification rates in HIV-negative patients, by year relative to rapid diagnostic test roll-out, Cape Town, South Africa, 2010&#x02013;2014</p></caption><p>HIV: human immunodeficiency virus.</p><p>Notes: Patients who initiated tuberculosis treatment in the year before the Xpert&#x000ae; MTB/RIF test (Cepheid, Sunnyvale, United States of America) roll-out date for their clinic were assigned to year&#x000a0;0, those who started treatment in the first year after roll-out for their clinic were assigned to year&#x000a0;1 and so on up to year&#x000a0;4 (<xref ref-type="fig" rid="F1">Fig.&#x000a0;1</xref>). Treatment was empirical when no test gave a positive result or no test was performed.</p><graphic xlink:href="BLT.16.185314-F5"/></fig><fig id="F6" fig-type="figure" orientation="portrait" position="float"><label>Fig. 6</label><caption><p>Tuberculosis notification rates in HIV-positive patients, by year relative to rapid diagnostic test roll-out, Cape Town, South Africa, 2010&#x02013;2014</p></caption><p>HIV: human immunodeficiency virus.</p><p>Notes: Patients who initiated tuberculosis treatment in the year before the Xpert&#x000ae; MTB/RIF test (Cepheid, Sunnyvale, United States of America) roll-out date for their clinic were assigned to year&#x000a0;0, those who started treatment in the first year after roll-out for their clinic were assigned to year&#x000a0;1 and so on up to year&#x000a0;4 (<xref ref-type="fig" rid="F1">Fig.&#x000a0;1</xref>). Treatment was empirical when no test gave a positive result or no test was performed.</p><graphic xlink:href="BLT.16.185314-F6"/></fig><p>Multivariable logistic regression analysis showed that the odds of empirical tuberculosis treatment were 2.75-fold higher in HIV-positive than HIV-negative patients (adjusted odds ratio: 2.75; 95% confidence interval: 2.55&#x02013;2.98). Other factors associated with empirical treatment were all patients older than 45&#x000a0;years and female sex in HIV-infected patients. After adjusting for these factors, the odds of empirical treatment decreased with time relative to test roll-out (<xref ref-type="table" rid="T4">Table&#x000a0;4</xref>). There was no evidence to support a further reduction in odds between years&#x000a0;2, 3 and 4 (<italic>P</italic>&#x02009;=&#x02009;0.22). When the analysis was performed separately in HIV-positive and HIV-negative patients, the same risk factors were identified (<xref ref-type="table" rid="T4">Table&#x000a0;4</xref>). Among HIV-positive patients, every 50-cells/mm<sup>3</sup> increase in CD4+ cell count at tuberculosis diagnosis was associated with 4% lower odds of empirical treatment. These results were found to be robust in the sensitivity analysis performed using a random effects model (details available from the corresponding author on request).</p><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4</label><caption><title>Risk factors associated with empirical tuberculosis treatment, Cape Town, South Africa, 2010&#x02013;2014</title></caption><table frame="hsides" rules="groups"><col width="118" span="1"/><col width="99" span="1"/><col width="56" span="1"/><col width="106" span="1"/><col width="56" span="1"/><col width="106" span="1"/><col width="56" span="1"/><thead><tr><th rowspan="3" valign="top" align="left" scope="col" colspan="1">Risk factor</th><th colspan="6" valign="top" align="center" scope="colgroup" rowspan="1">Risk of empirical treatment,<sup>a</sup> by multivariable logistic regression analysis<hr/></th></tr><tr><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1">HIV-negative patients<hr/></th><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1">HIV-positive patients<hr/></th><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1">All patients<hr/></th></tr><tr><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">aOR (95% CI)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><italic>P</italic>-value</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">aOR (95% CI)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><italic>P</italic>-value</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">aOR (95% CI)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><bold>Sex</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.92</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;&#x02009;0.001</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.15</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Female</td><td valign="top" align="center" rowspan="1" colspan="1">Reference</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Reference</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Reference</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Male</td><td valign="top" align="center" rowspan="1" colspan="1">1.00 (0.92&#x02013;1.08)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.92 (0.88&#x02013;0.97)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.97 (0.93&#x02013;1.01)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><bold>Age in years</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;&#x02009;0.001</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;&#x02009;0.001</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;&#x02009;0.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">15&#x02013;24</td><td valign="top" align="center" rowspan="1" colspan="1">Reference</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Reference</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Reference</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">25&#x02013;34</td><td valign="top" align="center" rowspan="1" colspan="1">0.93 (0.83&#x02013;1.04)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">1.13 (1.04&#x02013;1.22)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">1.04 (0.96&#x02013;1.12)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">35&#x02013;44</td><td valign="top" align="center" rowspan="1" colspan="1">1.02 (0.92&#x02013;1.14)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">1.22 (1.12&#x02013;1.34)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">1.12 (1.03&#x02013;1.22)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">45&#x02013;54</td><td valign="top" align="center" rowspan="1" colspan="1">1.32 (1.18&#x02013;1.47)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">1.37 (1.22&#x02013;1.54)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">1.31 (1.19&#x02013;1.44)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">55&#x02013;64</td><td valign="top" align="center" rowspan="1" colspan="1">1.77 (1.51&#x02013;2.07)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">1.44 (1.23&#x02013;1.68)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">1.64 (1.45&#x02013;1.87)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02265;&#x02009;65</td><td valign="top" align="center" rowspan="1" colspan="1">2.91 (2.56&#x02013;3.31)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">2.33 (1.65&#x02013;3.29)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">2.89 (2.55&#x02013;3.27)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><bold>CD4+ T-lymphocyte count, per 50-cells/mm<sup>3</sup> increase</bold></td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">0.96 (0.96&#x02013;0.97)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;&#x02009;0.001</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><bold>Prior tuberculosis treatment</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.54</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;&#x02009;0.001</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.02</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">Reference</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Reference</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Reference</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">0.97 (0.87&#x02013;1.07)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">1.20 (1.11&#x02013;1.30)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">1.09 (1.02&#x02013;1.18)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><bold>Year relative to rapid test roll-out<sup>b</sup></bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;&#x02009;0.001<sup>c</sup></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;&#x02009;0.001<sup>c</sup></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;&#x02009;0.001<sup>c</sup></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">Reference</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Reference</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Reference</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">0.73 (0.64&#x02013;0.82)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.69 (0.63&#x02013;0.77)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.70 (0.64&#x02013;0.77)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">0.55 (0.48&#x02013;0.61)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.58 (0.51&#x02013;0.65)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.56 (0.51&#x02013;0.62)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">0.47 (0.41&#x02013;0.54)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.55 (0.47&#x02013;0.64)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.51 (0.45&#x02013;0.58)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">4</td><td valign="top" align="center" rowspan="1" colspan="1">0.48 (0.32&#x02013;0.71)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.54 (0.41&#x02013;0.72)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.52 (0.39&#x02013;0.68)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p>aOR: adjusted odds ratio; CI: confidence interval; HIV: human immunodeficiency virus; N/A: not applicable.</p><p><sup>a</sup> Treatment was empirical when no test gave a positive result or no test was performed.</p><p><sup>b</sup> Patients who initiated tuberculosis treatment in the year before the Xpert&#x000ae; MTB/RIF test (Cepheid, Sunnyvale, United States of America) roll-out date for their clinic were assigned to year&#x000a0;0, those who started treatment in the first year after roll-out for their clinic were assigned to year&#x000a0;1 and so on up to year&#x000a0;4 (<xref ref-type="fig" rid="F1">Fig.&#x000a0;1</xref>).</p><p><sup>c</sup>
<italic>P</italic>-values calculated using the Wald test were also &#x0003c;&#x02009;0.001 for each roll-out year relative to year&#x000a0;0.</p></table-wrap-foot></table-wrap></sec><sec sec-type="discussion"><title>Discussion</title><p>We found that the introduction of the Xpert&#x000ae; test as the first-line diagnostic test for tuberculosis in a large population cohort led to this test becoming the primary method of diagnosis in three quarters of adults treated for drug-sensitive pulmonary tuberculosis. In addition, the rate of bacteriologically confirmed disease increased following the introduction of the test and the rate of empirical treatment decreased, resulting in a net decline in the total notification rate for pulmonary tuberculosis. These changes occurred cumulatively with test roll-out and stabilized after 3&#x000a0;years.</p><p>Few evaluations of the impact of routine Xpert&#x000ae; testing in programmatic settings have been published and most documented difficulties with roll-out and implementation.<xref rid="R24" ref-type="bibr"><sup>24</sup></xref><sup>&#x02013;</sup><xref rid="R29" ref-type="bibr"><sup>29</sup></xref> Increased proportions of bacteriological confirmation and less empirical treatment were reported in Nepal and India but an increase in the case notification rate was reported only in India.<xref rid="R30" ref-type="bibr"><sup>30</sup></xref><sup>,</sup><xref rid="R31" ref-type="bibr"><sup>31</sup></xref> Moreover, the four large randomized clinical trials performed to date all reported increased proportions of bacteriological confirmation but only one, performed in Cape Town,<xref rid="R11" ref-type="bibr"><sup>11</sup></xref> found that the number of patients diagnosed with tuberculosis increased.<xref rid="R10" ref-type="bibr"><sup>10</sup></xref><sup>&#x02013;</sup><xref rid="R13" ref-type="bibr"><sup>13</sup></xref></p><p>Our data from a programmatic setting in Cape Town are consistent with previous findings: routine use of the rapid test did not lead to an increase in the tuberculosis notification rate but was temporally associated with an increased bacteriological confirmation rate and a decrease in empirical treatment. The net effect was an apparent decline in the total tuberculosis notification rate. We previously reported that notification rates have decreased since 2010 in both HIV-negative and HIV-positive individuals.<xref rid="R32" ref-type="bibr"><sup>32</sup></xref> There are two potential, complementary explanations: (i)&#x000a0;the incidence of tuberculosis decreased (assuming access to diagnosis did not change); and (ii)&#x000a0;empirical treatment decreased. It was not possible to separate the contributions of these factors using our data. However, the observation that the rate of bacteriologically confirmed tuberculosis remained stable with the increasing use of a more sensitive test suggests that the incidence of tuberculosis may have decreased. A possible underlying mechanism could be greater use of antiretroviral therapy in the HIV-infected population &#x02013; coverage increased from 0% in 2004 to 63% in 2013 in Cape Town.<xref rid="R32" ref-type="bibr"><sup>32</sup></xref> However, the decline in tuberculosis notification rates we observed was not affected by HIV status, which does not support this explanation. In contrast, the possibility that the empirical treatment rate decreased with the test roll-out is supported by our observation that the decline in this rate slowed gradually during roll-out and then stabilized. This may reflect the time needed to fully implement the new test and, possibly, to apply the new diagnostic algorithm. If the decrease in the tuberculosis notification rate we observed were mainly attributable to a reduction in empirical treatment, we would expect the decline to stabilize within 3 to 4&#x000a0;years of the test being introduced at the last clinic (i.e. by the end of 2017). If the decline continues thereafter, it is probably attributable to another factor, such as declining incidence.<xref rid="R12" ref-type="bibr"><sup>12</sup></xref></p><p>The main limitation of our study was its inability to determine whether the decline in empirical treatment represented a decline in false-positive or true-positive diagnoses. The latter could have occurred because clinicians overestimated the negative predictive value of the rapid test. Interestingly, the proportional decline in empirical treatment was smaller among HIV-infected patients, in whom the test is less sensitive.<xref rid="R3" ref-type="bibr"><sup>3</sup></xref> Clinicians may have been reluctant to miss active tuberculosis disease in this vulnerable population, thereby increasing the number of false-positive diagnoses. Our lack of data on presumptive tuberculosis patients precluded an evaluation of whether roll-out of the test led to the identification and treatment of patients who would otherwise not have been treated. Moreover, we were not able to investigate the impact of symptomatology on the likelihood of empirical treatment (no data) or of the time to treatment initiation (incomplete recording of sputum collection dates). The apparent decrease in previously treated patients was probably due to misclassification following abolition of the distinct retreatment regimen.</p><p>In conclusion, routine use of the Xpert&#x000ae; test in a setting with a high prevalence of tuberculosis and HIV infection was associated with a halving of the empirical treatment rate. This reduction occurred gradually following the introduction of the test, probably due to the time needed for full implementation of a new diagnostic algorithm. More than a quarter of HIV-infected patients were still treated empirically, which highlights the difficulty of diagnosing tuberculosis in this group.</p></sec></body><back><ack><title>Acknowledgements</title><p>We thank Carl Morrow, Desmond Tutu HIV Centre, Institute for Infectious Diseases and Molecular Medicine, University of Cape Town, and Gareth Bowers, Cape Town. Sabine Hermans is also affiliated with the Amsterdam Institute for Global Health and Development and the Department of Internal Medicine, Makerere University College of Health Sciences, Kampala, Uganda. Frank Cobelens is also affiliated with the KNCV Tuberculosis Foundation in The Hague. Robin Wood is also affiliated with the Department of Medicine, University of Cape Town and the Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene &#x00026; Tropical Medicine.</p></ack><fn-group><title>Funding:</title><fn fn-type="supported-by"><p>This work was supported by the European Union (Marie Curie International Outgoing Fellowship for Career Development PIOF-GA-2012&#x02013;332311 to SH), the South African Medical Research Council (MRC-RFAUFSP-01&#x02013;2013/CCAMP to RW), the National Institutes of Health (R01AI058736 and R01AI093269 to RW) and the Bill &#x00026; Melinda Gates Foundation (OPP1116641 to RW).</p></fn></fn-group><fn-group><title>Competing interests:</title><fn fn-type="financial-disclosure"><p>None declared.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal"><string-name><surname>Boehme</surname>
<given-names>CC</given-names></string-name>, <string-name><surname>Nicol</surname>
<given-names>MP</given-names></string-name>, <string-name><surname>Nabeta</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Michael</surname>
<given-names>JS</given-names></string-name>, <string-name><surname>Gotuzzo</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Tahirli</surname>
<given-names>R</given-names></string-name>, <etal>et al.</etal>
<article-title>Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study.</article-title>
<source>Lancet</source>. <year>2011</year>
<month>4</month>
<day>30</day>;<volume>377</volume>(<issue>9776</issue>):<fpage>1495</fpage>&#x02013;<lpage>505</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(11)60438-8</pub-id><pub-id pub-id-type="pmid">21507477</pub-id></mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal"><string-name><surname>Boehme</surname>
<given-names>CC</given-names></string-name>, <string-name><surname>Nabeta</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Hillemann</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Nicol</surname>
<given-names>MP</given-names></string-name>, <string-name><surname>Shenai</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Krapp</surname>
<given-names>F</given-names></string-name>, <etal>et al.</etal>
<article-title>Rapid molecular detection of tuberculosis and rifampin resistance.</article-title>
<source>N Engl J Med</source>. <year>2010</year>
<month>9</month>
<day>9</day>;<volume>363</volume>(<issue>11</issue>):<fpage>1005</fpage>&#x02013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa0907847</pub-id><pub-id pub-id-type="pmid">20825313</pub-id></mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal"><string-name><surname>Steingart</surname>
<given-names>KR</given-names></string-name>, <string-name><surname>Schiller</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Horne</surname>
<given-names>DJ</given-names></string-name>, <string-name><surname>Pai</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Boehme</surname>
<given-names>CC</given-names></string-name>, <string-name><surname>Dendukuri</surname>
<given-names>N</given-names></string-name>. <article-title>Xpert&#x000ae; MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.</article-title>
<source>Cochrane Database Syst Rev</source>. <year>2014</year>
<month>1</month>
<day>21</day>;<volume>1</volume>(<issue>1</issue>):<fpage>CD009593</fpage>.<pub-id pub-id-type="pmid">24448973</pub-id></mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="web">WHO endorses new rapid tuberculosis test: a major milestone for global TB diagnosis and care. News release. Geneva: World Health Organization; 2010. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/mediacentre/news/releases/2010/tb_test_20101208/en/">http://www.who.int/mediacentre/news/releases/2010/tb_test_20101208/en/</ext-link> [cited 2014 Dec 15].</mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal"><string-name><surname>Albert</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Nathavitharana</surname>
<given-names>RR</given-names></string-name>, <string-name><surname>Isaacs</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Pai</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Denkinger</surname>
<given-names>CM</given-names></string-name>, <string-name><surname>Boehme</surname>
<given-names>CC</given-names></string-name>. <article-title>Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better?</article-title>
<source>Eur Respir J</source>. <year>2016</year>
<month>8</month>;<volume>48</volume>(<issue>2</issue>):<fpage>516</fpage>&#x02013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1183/13993003.00543-2016</pub-id><pub-id pub-id-type="pmid">27418550</pub-id></mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="web">Priorities for tuberculosis research: a report of the disease reference group report on TB, leprosy and Buruli ulcer. Geneva: World Health Organization; 2013. Available from: <ext-link ext-link-type="uri" xlink:href="http://apps.who.int/iris/bitstream/10665/85888/1/9789241505970_eng.pdf">http://apps.who.int/iris/bitstream/10665/85888/1/9789241505970_eng.pdf</ext-link>. [cited 2017 Apr 18].</mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal"><string-name><surname>Menzies</surname>
<given-names>NA</given-names></string-name>, <string-name><surname>Cohen</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Lin</surname>
<given-names>HH</given-names></string-name>, <string-name><surname>Murray</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Salomon</surname>
<given-names>JA</given-names></string-name>. <article-title>Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation.</article-title>
<source>PLoS Med</source>. <year>2012</year>;<volume>9</volume>(<issue>11</issue>):<fpage>e1001347</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pmed.1001347</pub-id><pub-id pub-id-type="pmid">23185139</pub-id></mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal"><string-name><surname>Meyer-Rath</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Schnippel</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Long</surname>
<given-names>L</given-names></string-name>, <string-name><surname>MacLeod</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Sanne</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Stevens</surname>
<given-names>W</given-names></string-name>, <etal>et al.</etal>
<article-title>The impact and cost of scaling up GeneXpert MTB/RIF in South Africa.</article-title>
<source>PLoS One</source>. <year>2012</year>;<volume>7</volume>(<issue>5</issue>):<fpage>e36966</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0036966</pub-id><pub-id pub-id-type="pmid">22693561</pub-id></mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal"><string-name><surname>Dowdy</surname>
<given-names>DW</given-names></string-name>, <string-name><surname>Davis</surname>
<given-names>JL</given-names></string-name>, <string-name><surname>den Boon</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Walter</surname>
<given-names>ND</given-names></string-name>, <string-name><surname>Katamba</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Cattamanchi</surname>
<given-names>A</given-names></string-name>. <article-title>Population-level impact of same-day microscopy and Xpert MTB/RIF for tuberculosis diagnosis in Africa.</article-title>
<source>PLoS One</source>. <year>2013</year>
<month>8</month>
<day>12</day>;<volume>8</volume>(<issue>8</issue>):<fpage>e70485</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0070485</pub-id><pub-id pub-id-type="pmid">23950942</pub-id></mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal"><string-name><surname>Theron</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Zijenah</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Chanda</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Clowes</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Rachow</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Lesosky</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal>; <collab>TB-NEAT team</collab>. <article-title>Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial.</article-title>
<source>Lancet</source>. <year>2014</year>
<month>2</month>
<day>1</day>;<volume>383</volume>(<issue>9915</issue>):<fpage>424</fpage>&#x02013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(13)62073-5</pub-id><pub-id pub-id-type="pmid">24176144</pub-id></mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal"><string-name><surname>Cox</surname>
<given-names>HS</given-names></string-name>, <string-name><surname>Mbhele</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Mohess</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Whitelaw</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Muller</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Zemanay</surname>
<given-names>W</given-names></string-name>, <etal>et al.</etal>
<article-title>Impact of Xpert MTB/RIF for TB diagnosis in a primary care clinic with high TB and HIV prevalence in South Africa: a pragmatic randomised trial.</article-title>
<source>PLoS Med</source>. <year>2014</year>
<month>11</month>
<day>25</day>;<volume>11</volume>(<issue>11</issue>):<fpage>e1001760</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pmed.1001760</pub-id><pub-id pub-id-type="pmid">25423041</pub-id></mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="journal"><string-name><surname>Durovni</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Saraceni</surname>
<given-names>V</given-names></string-name>, <string-name><surname>van den Hof</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Trajman</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Cordeiro-Santos</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Cavalcante</surname>
<given-names>S</given-names></string-name>, <etal>et al.</etal>
<article-title>Impact of replacing smear microscopy with Xpert MTB/RIF for diagnosing tuberculosis in Brazil: a stepped-wedge cluster-randomized trial.</article-title>
<source>PLoS Med</source>. <year>2014</year>
<month>12</month>
<day>9</day>;<volume>11</volume>(<issue>12</issue>):<fpage>e1001766</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pmed.1001766</pub-id><pub-id pub-id-type="pmid">25490549</pub-id></mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal"><string-name><surname>Churchyard</surname>
<given-names>GJ</given-names></string-name>, <string-name><surname>Stevens</surname>
<given-names>WS</given-names></string-name>, <string-name><surname>Mametja</surname>
<given-names>LD</given-names></string-name>, <string-name><surname>McCarthy</surname>
<given-names>KM</given-names></string-name>, <string-name><surname>Chihota</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Nicol</surname>
<given-names>MP</given-names></string-name>, <etal>et al.</etal>
<article-title>Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF.</article-title>
<source>Lancet Glob Health</source>. <year>2015</year>
<month>8</month>;<volume>3</volume>(<issue>8</issue>):<fpage>e450</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/S2214-109X(15)00100-X</pub-id><pub-id pub-id-type="pmid">26187490</pub-id></mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="journal"><string-name><surname>Theron</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Peter</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Dowdy</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Langley</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Squire</surname>
<given-names>SB</given-names></string-name>, <string-name><surname>Dheda</surname>
<given-names>K</given-names></string-name>. <article-title>Do high rates of empirical treatment undermine the potential effect of new diagnostic tests for tuberculosis in high-burden settings?</article-title>
<source>Lancet Infect Dis</source>. <year>2014</year>
<month>6</month>;<volume>14</volume>(<issue>6</issue>):<fpage>527</fpage>&#x02013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(13)70360-8</pub-id><pub-id pub-id-type="pmid">24438820</pub-id></mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="journal"><string-name><surname>Menzies</surname>
<given-names>NA</given-names></string-name>, <string-name><surname>Cohen</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Murray</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Salomon</surname>
<given-names>JA</given-names></string-name>. <article-title>Effect of empirical treatment on outcomes of clinical trials of diagnostic assays for tuberculosis.</article-title>
<source>Lancet Infect Dis</source>. <year>2015</year>
<month>1</month>;<volume>15</volume>(<issue>1</issue>):<fpage>16</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(14)71026-6</pub-id><pub-id pub-id-type="pmid">25541164</pub-id></mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="journal"><string-name><surname>Sun</surname>
<given-names>AY</given-names></string-name>, <string-name><surname>Denkinger</surname>
<given-names>CM</given-names></string-name>, <string-name><surname>Dowdy</surname>
<given-names>DW</given-names></string-name>. <article-title>The impact of novel tests for tuberculosis depends on the diagnostic cascade.</article-title>
<source>Eur Respir J</source>. <year>2014</year>
<month>11</month>;<volume>44</volume>(<issue>5</issue>):<fpage>1366</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1183/09031936.00111014</pub-id><pub-id pub-id-type="pmid">25186263</pub-id></mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="book"><source>Management and treatment of TB in adults and children older than 8 years. Circular No: H22/2013.</source>
<publisher-loc>Cape Town</publisher-loc>: <publisher-name>Western Cape Department of Health</publisher-name>; <year>2013</year>.</mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="web">City of Cape Town &#x02013; 2011 Census &#x02013; Cape Town. Cape Town: Strategic Development Information and GIS Department, City of Cape Town; 2011. Available from: <ext-link ext-link-type="uri" xlink:href="http://resource.capetown.gov.za/documentcentre/Documents/Maps%20and%20statistics/2011_Census_Cape_Town_Profile.pdf">http://resource.capetown.gov.za/documentcentre/Documents/Maps%20and%20statistics/2011_Census_Cape_Town_Profile.pdf</ext-link> [cited 2017 Apr 18].</mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="web">Stevens M, Sinanovic E, Regensberg L, Hislop M. HIV and AIDS, STI and TB in the private sector. Chapter 14. In: South African Health Review 2007. Durban: Health Systems Trust; 2007. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.hst.org.za/uploads/files/chap14_07.pdf">http://www.hst.org.za/uploads/files/chap14_07.pdf</ext-link> [cited 2017 Jan 30].</mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="book"><string-name><surname>Whitelaw</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Sturm</surname>
<given-names>W</given-names></string-name>. <chapter-title>Microbiological testing for <italic>Mycobacterium tuberculosis</italic>.</chapter-title> In: <string-name><surname>Schaaf</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Zumla</surname>
<given-names>A</given-names></string-name>, editors. <source>Tuberculosis: a comprehensive reference.</source>
<publisher-loc>London</publisher-loc>: <publisher-name>Saunders</publisher-name>; <year>2009</year>.</mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="web">National tuberculosis management guidelines 2009. Pretoria: National Department of Health, Republic of South Africa; 2009. Available from: <ext-link ext-link-type="uri" xlink:href="http://familymedicine.ukzn.ac.za/Libraries/Guidelines_Protocols/TB_Guidelines_2009.sflb.ashx">http://familymedicine.ukzn.ac.za/Libraries/Guidelines_Protocols/TB_Guidelines_2009.sflb.ashx</ext-link> [cited 2013 Nov 04].</mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="web">District council projections 2002&#x02013;2016 [spreadsheet]. Pretoria: Statistics South Africa, National Department of Health, Health Information Systems Programme; 2010. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.statssa.gov.za/publications/P0302/District_Council_projection_by_sex_and_age_(2002-2016).xlsx">http://www.statssa.gov.za/publications/P0302/District_Council_projection_by_sex_and_age_(2002-2016).xlsx</ext-link> [cited 2017 Apr 18].</mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="web">AIDS models [Internet]. Cape Town: Actuarial Society of South Africa; 2008. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.actuarialsociety.org.za/Societyactivities/CommitteeActivities/DemographyEpidemiologyCommittee/Models.aspx">http://www.actuarialsociety.org.za/Societyactivities/CommitteeActivities/DemographyEpidemiologyCommittee/Models.aspx</ext-link> [cited 2012 Jul 17].</mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="journal"><string-name><surname>Creswell</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Codlin</surname>
<given-names>AJ</given-names></string-name>, <string-name><surname>Andre</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Micek</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Bedru</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Carter</surname>
<given-names>EJ</given-names></string-name>, <etal>et al.</etal>
<article-title>Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries.</article-title>
<source>BMC Infect Dis</source>. <year>2014</year>
<month>1</month>
<day>2</day>;<volume>14</volume>(<issue>1</issue>):<fpage>2</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2334-14-2</pub-id><pub-id pub-id-type="pmid">24383553</pub-id></mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="journal"><string-name><surname>Durovni</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Saraceni</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Cordeiro-Santos</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Cavalcante</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Soares</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Louren&#x000e7;o</surname>
<given-names>C</given-names></string-name>, <etal>et al.</etal>
<article-title>Operational lessons drawn from pilot implementation of Xpert MTB/Rif in Brazil.</article-title>
<source>Bull World Health Organ</source>. <year>2014</year>
<month>8</month>
<day>1</day>;<volume>92</volume>(<issue>8</issue>):<fpage>613</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.2471/BLT.13.131409</pub-id><pub-id pub-id-type="pmid">25177076</pub-id></mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="journal"><string-name><surname>Cowan</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Michel</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Manhi&#x000e7;a</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Monivo</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Saize</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Creswell</surname>
<given-names>J</given-names></string-name>, <etal>et al.</etal>
<article-title>Implementing rapid testing for tuberculosis in Mozambique.</article-title>
<source>Bull World Health Organ</source>. <year>2015</year>
<month>2</month>
<day>1</day>;<volume>93</volume>(<issue>2</issue>):<fpage>125</fpage>&#x02013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.2471/BLT.14.138560</pub-id><pub-id pub-id-type="pmid">25883406</pub-id></mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="journal"><string-name><surname>Sikhondze</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Dlamini</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Khumalo</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Maphalala</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Dlamini</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Zikalala</surname>
<given-names>T</given-names></string-name>, <etal>et al.</etal>
<article-title>Countrywide roll-out of Xpert(&#x000ae;) MTB/RIF in Swaziland: the first three years of implementation.</article-title>
<source>Public Health Action</source>. <year>2015</year>
<month>6</month>
<day>21</day>;<volume>5</volume>(<issue>2</issue>):<fpage>140</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.5588/pha.15.0001</pub-id><pub-id pub-id-type="pmid">26400386</pub-id></mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="journal"><string-name><surname>Molapo</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Berrie</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Marokane</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Magida</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Scott</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Stevens</surname>
<given-names>W</given-names></string-name>. <article-title>GeneXpert module failures: South Africa&#x02019;s Xpert MTB/RIF national programme experience and impact on costs.</article-title>
<source>Int J Tuberc Lung Dis</source>. <year>2014</year>
<month>11</month>;<volume>18</volume>(<issue>11</issue>) <supplement>suppl 1</supplement>:<fpage>s395</fpage> Available from: <ext-link ext-link-type="uri" xlink:href="http://barcelona.worldlunghealth.org/programme/body/Abstract_Book_2014-Web.pdf">http://barcelona.worldlunghealth.org/programme/body/Abstract_Book_2014-Web.pdf</ext-link>
<comment>[cited 2017 Apr 18]</comment>.</mixed-citation></ref><ref id="R29"><label>29</label><mixed-citation publication-type="journal"><string-name><surname>Hanrahan</surname>
<given-names>CF</given-names></string-name>, <string-name><surname>Haguma</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Ochom</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Kinera</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Cobelens</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Cattamanchi</surname>
<given-names>A</given-names></string-name>, <etal>et al.</etal>
<article-title>Implementation of Xpert MTB/RIF in Uganda: missed opportunities to improve diagnosis of tuberculosis.</article-title>
<source>Open Forum Infect Dis</source>. <year>2016</year>
<month>5</month>
<day>12</day>;<volume>3</volume>(<issue>2</issue>):<fpage>ofw068</fpage>. <pub-id pub-id-type="doi">10.1093/ofid/ofw068</pub-id><pub-id pub-id-type="pmid">27186589</pub-id></mixed-citation></ref><ref id="R30"><label>30</label><mixed-citation publication-type="journal"><string-name><surname>Creswell</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Rai</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Wali</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Sudrungrot</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Adhikari</surname>
<given-names>LM</given-names></string-name>, <string-name><surname>Pant</surname>
<given-names>R</given-names></string-name>, <etal>et al.</etal>
<article-title>Introducing new tuberculosis diagnostics: the impact of Xpert(&#x000ae;) MTB/RIF testing on case notifications in Nepal.</article-title>
<source>Int J Tuberc Lung Dis</source>. <year>2015</year>
<month>5</month>;<volume>19</volume>(<issue>5</issue>):<fpage>545</fpage>&#x02013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.5588/ijtld.14.0775</pub-id><pub-id pub-id-type="pmid">25868022</pub-id></mixed-citation></ref><ref id="R31"><label>31</label><mixed-citation publication-type="journal"><string-name><surname>Sachdeva</surname>
<given-names>KS</given-names></string-name>, <string-name><surname>Raizada</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Sreenivas</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Van&#x02019;t Hoog</surname>
<given-names>AH</given-names></string-name>, <string-name><surname>van den Hof</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Dewan</surname>
<given-names>PK</given-names></string-name>, <etal>et al.</etal>
<article-title>Use of Xpert MTB/RIF in decentralized public health settings and its effect on pulmonary TB and DR-TB case finding in India.</article-title>
<source>PLoS One</source>. <year>2015</year>
<month>5</month>
<day>21</day>;<volume>10</volume>(<issue>5</issue>):<fpage>e0126065</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0126065</pub-id><pub-id pub-id-type="pmid">25996389</pub-id></mixed-citation></ref><ref id="R32"><label>32</label><mixed-citation publication-type="journal"><string-name><surname>Hermans</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Boulle</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Caldwell</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Pienaar</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Wood</surname>
<given-names>R</given-names></string-name>. <article-title>Temporal trends in TB notification rates during ART scale-up in Cape Town: an ecological analysis.</article-title>
<source>J Int AIDS Soc</source>. <year>2015</year>
<month>9</month>
<day>25</day>;<volume>18</volume>(<issue>1</issue>):<fpage>20240</fpage>. <pub-id pub-id-type="doi">10.7448/IAS.18.1.20240</pub-id><pub-id pub-id-type="pmid">26411694</pub-id></mixed-citation></ref></ref-list></back></article>